AU4238600A - Beta-lactamase inhibiting compounds - Google Patents
Beta-lactamase inhibiting compounds Download PDFInfo
- Publication number
- AU4238600A AU4238600A AU42386/00A AU4238600A AU4238600A AU 4238600 A AU4238600 A AU 4238600A AU 42386/00 A AU42386/00 A AU 42386/00A AU 4238600 A AU4238600 A AU 4238600A AU 4238600 A AU4238600 A AU 4238600A
- Authority
- AU
- Australia
- Prior art keywords
- cio
- compound
- heterocycle
- alkyl
- alkanoyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 212
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 21
- 108090000204 Dipeptidase 1 Proteins 0.000 title abstract description 3
- 102000006635 beta-lactamase Human genes 0.000 title abstract description 3
- 238000000034 method Methods 0.000 claims abstract description 53
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 241000124008 Mammalia Species 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 5
- 230000002708 enhancing effect Effects 0.000 claims abstract description 5
- -1 hydroxy, cyano, cyanato, nitro, mercapto Chemical class 0.000 claims description 155
- 229910052739 hydrogen Inorganic materials 0.000 claims description 83
- 125000000623 heterocyclic group Chemical group 0.000 claims description 73
- 239000001257 hydrogen Substances 0.000 claims description 70
- 125000000217 alkyl group Chemical group 0.000 claims description 68
- 125000004423 acyloxy group Chemical group 0.000 claims description 58
- 125000003118 aryl group Chemical group 0.000 claims description 55
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 55
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 43
- 125000003545 alkoxy group Chemical group 0.000 claims description 39
- 125000001589 carboacyl group Chemical group 0.000 claims description 39
- 230000003115 biocidal effect Effects 0.000 claims description 35
- 125000003342 alkenyl group Chemical group 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 33
- 125000001475 halogen functional group Chemical group 0.000 claims description 32
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 29
- 125000000304 alkynyl group Chemical group 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 150000002431 hydrogen Chemical class 0.000 claims description 25
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 21
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 229920002554 vinyl polymer Polymers 0.000 claims description 12
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 11
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 7
- 229960003022 amoxicillin Drugs 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 7
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- 229960000723 ampicillin Drugs 0.000 claims description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 5
- 241000588914 Enterobacter Species 0.000 claims description 4
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims description 4
- 229960005361 cefaclor Drugs 0.000 claims description 4
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims description 4
- 229960003866 cefaloridine Drugs 0.000 claims description 4
- 229960004261 cefotaxime Drugs 0.000 claims description 4
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims description 4
- 229960000484 ceftazidime Drugs 0.000 claims description 4
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 claims description 4
- 229960001991 ceftizoxime Drugs 0.000 claims description 4
- 229960001668 cefuroxime Drugs 0.000 claims description 4
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 4
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 4
- 229940106164 cephalexin Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229960002292 piperacillin Drugs 0.000 claims description 4
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims description 4
- 241000588923 Citrobacter Species 0.000 claims description 3
- 241000607720 Serratia Species 0.000 claims description 3
- 238000013160 medical therapy Methods 0.000 claims description 3
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 claims description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 14
- 230000015572 biosynthetic process Effects 0.000 abstract description 11
- 238000003786 synthesis reaction Methods 0.000 abstract description 11
- 239000003782 beta lactam antibiotic agent Substances 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 4
- 239000002132 β-lactam antibiotic Substances 0.000 abstract 1
- 229940124586 β-lactam antibiotics Drugs 0.000 abstract 1
- 150000003952 β-lactams Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 76
- 238000005481 NMR spectroscopy Methods 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 49
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 46
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 44
- 239000011734 sodium Substances 0.000 description 42
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 36
- 150000003457 sulfones Chemical class 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 235000019439 ethyl acetate Nutrition 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 125000004076 pyridyl group Chemical group 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 125000005843 halogen group Chemical group 0.000 description 18
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 15
- 239000010410 layer Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 13
- 229910052708 sodium Inorganic materials 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000003826 tablet Substances 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- VVDUZZGYBOWDSQ-UHFFFAOYSA-M eschenmoser's salt Chemical compound [I-].C[N+](C)=C VVDUZZGYBOWDSQ-UHFFFAOYSA-M 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 0 C[C@@](*1*(*)C1)C(C=O)=CS[C@@](C1=Cc2ccccn2)NC1=O Chemical compound C[C@@](*1*(*)C1)C(C=O)=CS[C@@](C1=Cc2ccccn2)NC1=O 0.000 description 6
- 101000740462 Escherichia coli Beta-lactamase TEM Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 239000003039 volatile agent Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 5
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 108020004256 Beta-lactamase Proteins 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 4
- 235000019799 monosodium phosphate Nutrition 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000010979 pH adjustment Methods 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- YLSSVFGTKZXLPA-UHFFFAOYSA-N 2-(1-benzyl-2-ethyl-3-oxamoylbenzo[g]indol-4-yl)oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)C=C3C=CC=CC3=C2N1CC1=CC=CC=C1 YLSSVFGTKZXLPA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000588697 Enterobacter cloacae Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- AKQOBHZKBDHWQI-BZEFIUHZSA-N O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O Chemical compound O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O AKQOBHZKBDHWQI-BZEFIUHZSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical group [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940127108 compound 5g Drugs 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 3
- SKRDXYBATCVEMS-UHFFFAOYSA-N isopropyl nitrite Chemical compound CC(C)ON=O SKRDXYBATCVEMS-UHFFFAOYSA-N 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- MKDJIADBNUOBJH-UHFFFAOYSA-N octanoic acid;rhodium Chemical compound [Rh].[Rh].CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCC(O)=O MKDJIADBNUOBJH-UHFFFAOYSA-N 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229910001414 potassium ion Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000010948 rhodium Substances 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- LHNIIDJCEODSHA-OQRUQETBSA-N (6r,7r)-3-[(e)-2-(2,4-dinitrophenyl)ethenyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)\C=C\C=1C(=CC(=CC=1)[N+]([O-])=O)[N+]([O-])=O)C(=O)CC1=CC=CS1 LHNIIDJCEODSHA-OQRUQETBSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
- 125000006039 1-hexenyl group Chemical group 0.000 description 2
- 125000006023 1-pentenyl group Chemical group 0.000 description 2
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- NKFMHVSOHCEONZ-UHFFFAOYSA-N 2-(triphenyl-$l^{5}-phosphanylidene)acetamide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)N)C1=CC=CC=C1 NKFMHVSOHCEONZ-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- 125000006040 2-hexenyl group Chemical group 0.000 description 2
- 125000006024 2-pentenyl group Chemical group 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
- 125000006041 3-hexenyl group Chemical group 0.000 description 2
- 125000006042 4-hexenyl group Chemical group 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 125000006043 5-hexenyl group Chemical group 0.000 description 2
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229940123930 Lactamase inhibitor Drugs 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 101100521345 Mus musculus Prop1 gene Proteins 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 108010087702 Penicillinase Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108700017836 Prophet of Pit-1 Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- ZWZUFQPXYVYAFO-UHFFFAOYSA-N Tert-butyl (triphenylphosphoranylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC(C)(C)C)C1=CC=CC=C1 ZWZUFQPXYVYAFO-UHFFFAOYSA-N 0.000 description 2
- ONSQLDCEJIIUJS-XVFCMESISA-N [(2r,3s,4r,5r)-5-(2-amino-4-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound NC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 ONSQLDCEJIIUJS-XVFCMESISA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 2
- YGBFLZPYDUKSPT-MRVPVSSYSA-N cephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C[C@H]21 YGBFLZPYDUKSPT-MRVPVSSYSA-N 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940038649 clavulanate potassium Drugs 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- IEARPTNIYZTWOZ-UHFFFAOYSA-N ethene Chemical compound [CH-]=C IEARPTNIYZTWOZ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 125000004970 halomethyl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 229950009506 penicillinase Drugs 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 2
- 229960003865 tazobactam Drugs 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- 229940029284 trichlorofluoromethane Drugs 0.000 description 2
- IUNXOGIHFLDANL-UHFFFAOYSA-M triphenyl(pyridin-2-ylmethyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)CC1=CC=CC=N1 IUNXOGIHFLDANL-UHFFFAOYSA-M 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- CCRXGVYICNOVAM-UHFFFAOYSA-N (2-amino-2-oxoethyl)-triphenylphosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC(=O)N)C1=CC=CC=C1 CCRXGVYICNOVAM-UHFFFAOYSA-N 0.000 description 1
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- COXVPYKZDDKVRF-ULQDDVLXSA-N (4,4-difluorocyclohexyl)methyl N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C=O)NC(=O)OCC2CCC(CC2)(F)F COXVPYKZDDKVRF-ULQDDVLXSA-N 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- WXTSYRSZKUFAOX-LWOQYNTDSA-N (6r)-4-hydroxy-5-thia-1-azabicyclo[4.2.0]octan-8-one Chemical compound S1C(O)CCN2C(=O)C[C@H]21 WXTSYRSZKUFAOX-LWOQYNTDSA-N 0.000 description 1
- MAFIPFSQYBWLAM-BAFYGKSASA-N (6r)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid Chemical compound OC(=O)C1C=CS[C@@H]2CC(=O)N12 MAFIPFSQYBWLAM-BAFYGKSASA-N 0.000 description 1
- QBTROWHSMGZXCV-RQURQNPSSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecoxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QBTROWHSMGZXCV-RQURQNPSSA-N 0.000 description 1
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 1
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XOHZHMUQBFJTNH-UHFFFAOYSA-N 1-methyl-2h-tetrazole-5-thione Chemical compound CN1N=NN=C1S XOHZHMUQBFJTNH-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 1
- YLLRPQWLASQXSI-UHFFFAOYSA-N 3-(4b,8a,9,9a-tetrahydro-4aH-pyrido[2,3-b]indol-4-ylamino)phenol Chemical compound Oc1cccc(NC2=CC=NC3NC4C=CC=CC4C23)c1 YLLRPQWLASQXSI-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- XDCOYBQVEVSNNB-UHFFFAOYSA-N 4-[(7-naphthalen-2-yl-1-benzothiophen-2-yl)methylamino]butanoic acid Chemical compound OC(=O)CCCNCc1cc2cccc(-c3ccc4ccccc4c3)c2s1 XDCOYBQVEVSNNB-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- NZSQBRZWARZNQH-ZWOACCQCSA-N C1(CC1)NC(=O)O[C@H]1C(C2CC[C@]3([C@@]4(CC[C@@]5(C(C4CCC3[C@]2(CC1)C)[C@@H](CC5)[C@H](C)O)C(=O)O)C)C)(C)C Chemical compound C1(CC1)NC(=O)O[C@H]1C(C2CC[C@]3([C@@]4(CC[C@@]5(C(C4CCC3[C@]2(CC1)C)[C@@H](CC5)[C@H](C)O)C(=O)O)C)C)(C)C NZSQBRZWARZNQH-ZWOACCQCSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 101710178035 Chorismate synthase 2 Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229940126559 Compound 4e Drugs 0.000 description 1
- 229940125761 Compound 6g Drugs 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 101710152694 Cysteine synthase 2 Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 238000005642 Gabriel synthesis reaction Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- ITLHXEGAYQFOHJ-UHFFFAOYSA-N [diazo(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(=[N+]=[N-])C1=CC=CC=C1 ITLHXEGAYQFOHJ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000005035 acylthio group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229940098164 augmentin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 229940126115 compound 4f Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006612 decyloxy group Chemical group 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- HDKCVDHYIIKWFM-UHFFFAOYSA-K octanoate;rhodium(3+) Chemical compound [Rh+3].CCCCCCCC([O-])=O.CCCCCCCC([O-])=O.CCCCCCCC([O-])=O HDKCVDHYIIKWFM-UHFFFAOYSA-K 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- ITDJKCJYYAQMRO-UHFFFAOYSA-L rhodium(2+);diacetate Chemical compound [Rh+2].CC([O-])=O.CC([O-])=O ITDJKCJYYAQMRO-UHFFFAOYSA-L 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RFMIKMMOLPNEDG-QVUDESDKSA-M tazobactam sodium Chemical compound [Na+].C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C([O-])=O)(=O)=O)N1C=CN=N1 RFMIKMMOLPNEDG-QVUDESDKSA-M 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- BFDBKMOZYNOTPK-UHFFFAOYSA-N vonoprazan Chemical compound C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1F BFDBKMOZYNOTPK-UHFFFAOYSA-N 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Cephalosporin Compounds (AREA)
Abstract
The invention provides compounds of formula (I) and (IV), wherein R1-R11 and A have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting beta -lactamase enzymes, for enhancing the activity of beta -lactam antibiotics, and for treating beta -lactam resistant bacterial infections in a mammal. The invention also provides pharmaceutical compositions, processes for preparing compounds of formula (I) and (IV), and novel intermediates useful for the synthesis of compounds of formula (I) and (IV).
Description
WO 00/63213 PCT/USOO/09929 BETA-LACTAMASE INHIBITING COMPOUNDS Related Application The invention described herein claims priority to U.S. Provisional 5 Application Ser. No. 60/129,482, filed 15 April 1999, under 35 U.S.C. 119. Background of the Invention The most important mechanism of microbial resistance to p lactam antibiotics is the bacterial production of p-lactamases, enzymes which 10 hydrolytically destroy p-lactam antibiotics, such as penicillins and cephalosporins. This type of resistance can be transferred horizontally by plasmids that are capable of rapidly spreading the resistance, not only to other members of the same strain, but even to other species. Due to such rapid gene transfer, a patient can become infected with different organisms, each possessing 15 the same p-lactamase. p-lactamase enzymes have been organized into four molecular classes: A, B, C, and D based on amino acid sequence. Class A, which includes RTEM and the p-lactamase of Staphylococcus aureus, class C, which includes the lactamase derived from P-99 Enterobacter cloacae, and class D are seine 20 hydrolases. Class A enzymes have a molecular weight of about 29 kDa and preferentially hydrolyze penicillins. The class B lactamases are metalloenzymes and have a broader substrate profile than the proteins in the other classes. Class C enzymes include the chromosomal cephalosporinases of Gram-negative bacteria and have molecular weights of approximately 39 kDa. The recently 25 recognized class D enzymes exhibit a unique substrate profile which differs significantly from both class A and class C. The class C cephalosporinases, in particular, are responsible for the resistance of gram negative bacteria to a variety of both traditional and newly designed antibiotics. The Enterobacter species, which possesses a class C 30 enzyme, is now the third greatest cause of nosocomial infections in the United States. This class of enzymes often has poor affinities for inhibitors of the class A enzymes, such as clavulanic acid, a commonly prescribed inhibitor, and to common in vitro inactivators, such as 6-p-iodopenicillanate. 1 WO 00/63213 PCT/USOO/09929 One strategy for overcoming this rapidly evolving bacterial resistance is the synthesis and administration of P-lactamase inhibitors. Frequently, P - lactamase inhibitors do not possess antibiotic activity themselves and are thus administered together with an antibiotic. One example of such a 5 synergistic mixture is the product sold under the trademark AUGMENTIN (amoxicillin, clavulanate potassium), which contains the antibiotic amoxicillin and the p-lactamase inhibitor, clavulanate potassium. There is a continued need for novel p-lactamase inhibitors, and in particular, for p-lactamase inhibitors that can be coadministered with a p-lactam 10 antibiotic. Summary of the Invention The invention provides a compound of formula I: 15 R1 R5 R2 O A R6R
COOR
4 20 (I) wherein: RI, R 2 , R 5 , and R 6 are each independently hydrogen, (CI-Clo)alkyl,
(C
2 -Clo)alkenyl, (C 2 -CIO)alkynyl, (C 3
-C
8 )cycloalkyl, (CI-CIO)alkoxy, (C CIO)alkanoyl, (CI-CIO)alkanoyloxy, (C-CIO)alkoxycarbonyl, aryl, heterocycle, 25 halo, cyano, nitro, -COORa, -C(=0)NRRC, -OC(=0)NRbR, NRbR, or -S(O)Rd; or R, and R 2 together with the carbon to which they are attached are (C 3 C)cycloalkyl or a heterocycle, wherein each (C 3
-C
8 )cycloalkyl or heterocycle is optionally substituted with (CI-CIO)alkyl, hydroxy, halo, (C 1 - CIO)alkoxy, (Cl CIO)alkanoyloxy, or (CI-CIO)alkoxycarbonyl; or R 5 and R 6 together with the 30 carbon to which they are attached are (C 3
-C
8 )cycloalkyl or a heterocycle, wherein each (C 3
-C
8 )cycloalkyl or heterocycle is optionally substituted with (C 1 CIO)alkyl, hydroxy, halo, (CI-CIO)alkoxy, (C 1 - CIO)alkanoyloxy, or (C 1 CIO)alkoxycarbonyl; 2 WO 00/63213 PCT/USOO/09929
R
3 is hydrogen, (CI-CIO)alkyl, (C 2 -Clo)alkenyl, (C 2 - C 1 O)alkynyl,
(C
3
-C
8 )cycloalkyl, (CI-C O)alkoxy, (CI-C O)alkanoyl, (CI-CIO)alkanoyloxy,
(C
CIO)alkoxycarbonyl, halo, cyano, nitro, aryl, heterocycle, -COORa, C(=O)NRbRe, -OC(=O)NRbR, NRbR, or -S(O).Rd; 5 R 4 is hydrogen; A is thio (S), sulfinyl (SO), or sulfonyl (SO 2 ); each n is independently 0, 1, or 2; each Ra is independently hydrogen, or (CI-CIO)alkyl; each Rb and R, is independently hydrogen, (CI-C 1 O)alkyl, (C 1 10 CIO)alkoxy, phenyl, benzyl, phenethyl, or (CI-CIO)alkanoyl; each Rd is independently (CI-CIO)alkyl, (CI-CIO)alkanoyl, aryl, heterocycle, aryl(C 1 -C)alkyl, heterocycle, or heterocycle(C-C)alkyl; wherein any (CI-CIO)alkyl, (C 2
-C
1 o)alkenyl, (C 2
-C
1 o)alkynyl, (C 3 C 8 )cycloalkyl, (CI-C O)alkoxy, (CI-CIO)alkanoyl, (Cl-CIO)alkanoyloxy, or (C 15 C 1 O)alkoxycarbonyl of R 1 , R 2 , R 3 , R,, and R 6 is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents independently selected from halo, hydroxy, cyano, cyanato, nitro, mercapto, oxo, aryl, heterocycle, (C 2
-C
6 )alkenyl, (C 2 C)alkynyl, (C -C 6 )alkoxy, (C -C)alkanoyl, (C-C 6 )alkanoyloxy, aryl(Cl
C
6 )alkanoyloxy, halo(C 1 -C)alkanoyloxy, heterocycle(Cl-C 6 )alkanoyloxy, 20 aryloxy, (heterocycle)oxy, -COORa, (C 3
-C
8 )cycloalkyl, -C(=O)NRbRc, OC(=0)NRbR, NRbR, and -S(O)Rd; and wherein any aryl is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents independently selected from halo, hydroxy, cyano, trifluoromethyl, nitro, trifluoromethoxy, (C-C 6 )alkyl, (C -C)alkanoyl, (C, 25 C)alkanoyloxy, (CI-C)alkoxycarbonyl, -COORa, -C(=O)NRbR, OC(=O)NRbR, NRbR, and -S(O)Rd; or a pharmaceutically acceptable salt thereof. The invention also provides a compound of formula IV: 30 3 WO 00/63213 PCT/USOO/09929
R
8
-
1 A N ~ Oj: R9 5
COOR
10 (IV) wherein:
R
7 and R, are each independently hydrogen, (C 1
-C
10 )alkyl, (C 2 CIO)alkenyl, (C 2 -CIO)alkynyl, (C 3
-C
8 )cycloalkyl, (CI-C O)alkoxy, (C 1 10 C 10 )alkanoyl, (CI-CIO)alkanoyloxy, (CI-Clo)alkoxycarbonyl, aryl, heterocycle, halo, cyano, nitro, -COORe, -C(=O)NRfRg, -OC(=O)NRfRg, NRfRg, or -S(O)lRh;
R
9 is cyano, -CH=NOR,, or a radical of the following formula Rj 15 Rk Rio is hydrogen; A is thio, sulfinyl, or sulfonyl; each n is independently 0, 1, or 2; 20 each R. is independently hydrogen, or (CI-C 1 O)alkyl; each Rf and R. is independently hydrogen, (Cl-C 10 )alkyl, (C 1 CIO)alkoxy, phenyl, benzyl, phenethyl, or (C 1 -CIO)alkanoyl; each Rh is independently (Cl-CIo)alkyl, phenyl, aryl(C,-C 6 )alkyl, heterocycle, or heterocycle(C-C 6 )alkyl; 25 R; is hydrogen or (C 1 -C)alkyl; and R. and Rk are each independently hydrogen, halo, cyano, nitro, aryl, heterocycle, (C 2
-C
6 )alkenyl, -COOR., -C(=O)NRfRg, -OC(=O)NRfRg, NRfRg, or -S(O).Rh; wherein any (C 1 -CIO)alkyl, (C 2 -CIO)alkenyl, (C 2 -CIO)alkynyl, (C 3 30 C 8 )cycloalkyl, (CI-CIO)alkoxy, (CI-CIO)alkanoyl, (CI-CIO)alkanoyloxy, or (C CIO)alkoxycarbonyl of R 7 , R 8 , R, and Rk is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents independently selected from halo, hydroxy, cyano, cyanato, nitro, mercapto, oxo, aryl, heterocycle, (C 2
-C
6 )alkenyl, (C 2 4 WO 00/63213 PCT/USOO/09929 C)alkynyl, (C,- C)alkoxy, (C 1 -C)alkanoyl, (C 1 -C)alkanoyloxy, aryl(C, C)alkanoyloxy, halo(C-C 6 )alkanoyloxy, heterocycle(C -C)alkanoyloxy, aryloxy, (heterocycle)oxy, (C 3
-C
8 )cycloalkyl, -COORe, -C(=O)NRfRg, OC(=O)NRrRg, NRhR', or -S(O)Rk; and 5 wherein any aryl is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents independently selected from halo, hydroxy, cyano, trifluoromethyl, nitro, trifluoromethoxy, (C -C 6 )alkyl, (CI-C)alkanoyl, (Cl C)alkanoyloxy, (C 1
-C
6 )alkoxycarbonyl,-COOR, -C(=O)NRfRg, -OC(=O)NRfRg, NRhRi, or -S(O)Rk; 10 or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition comprising a compound of formula I or IV, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier, as well as such a pharmaceutical composition that further comprises a p-lactam 15 antibiotic. The invention also provides a method comprising inhibiting a p lactamase by contacting (in vitro or in vivo) the p-lactamase with an effective amount of a compound of formula I or IV; or a pharmaceutically acceptable salt thereof. 20 The invention also provides a therapeutic method comprising inhibiting a p-lactamase in a mammal in need of such therapy, by administering an effective inhibitory amount of a compound of formula I or IV; or a pharmaceutically acceptable salt thereof. The invention also provides a method comprising enhancing the 25 activity of a p-lactam antibiotic, by administering the p-lactam antibiotic to a mammal in need thereof, in combination with an effective p-lactamase inhibiting amount of a compound of formula I or IV; or a pharmaceutically acceptable salt thereof. The invention also provides a method comprising treating a p 30 lactam resistant bacterial infection in a mammal, by administering an effective amount of a p-lactam antibiotic in combination with an effective p-lactamase inhibiting amount of a compound of formula I or IV; or a pharmaceutically acceptable salt thereof. 5 WO 00/63213 PCTIUS00/09929 The invention also provides a compound of formula I or IV for use in medical therapy (preferably for use in inhibiting a p-lactamase in a mammal, or for treating a p-lactam resistant bacterial infection in a mammal), as. well as the use of a compound of formula I or IV for the manufacture of a 5 medicament useful for inhibiting a p-lactamase in a human. The invention also provides processes and intermediates disclosed herein that are useful for preparing p-lactamase inhibitors of formula I or IV. Compounds of formula I and IV are useful as p-lactamase inhibitors for therapeutic applications. They are also useful as pharmacological 10 tools for in vitro or in vivo studies to investigate the mechanisms of antibiotic resistance, to help identify other therapeutic antibiotic agents or p-lactamase inhibitors, to identify which P-lactamases are being expressed by a given microorganism, or to selectively inhibit one or more p-lactamases in a microorganism. 15 Brief Description of the Figures Figure 1 Illustrates the synthesis of compounds of formula I Figure 2 Illustrates the synthesis of compounds of formula I Figure 3 Illustrates the synthesis of compounds of formula IV 20 Figure 4 Illustrates the synthesis of compounds of formulae I and IV 6 WO 00/63213 PCT/USOO/09929 Detailed Description of the Invention The following definitions are used, unless otherwise described: halo is fluoro, chloro, bromo, or iodo. Alkyl, alkoxy, alkenyl, etc. denote both 5 straight and branched groups. Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic. Heterocycle denotes a 6-10 membered unsaturated or saturated mono- bi- or tri-cyclic ring system comprising carbon and 1, 2, 3, or 4 heteroatoms selected from the group consisting of non-peroxide oxygen, sulfur, 10 and N(X) wherein each X is absent or is H, 0, (Cl-C 4 )alkyl, phenyl or benzyl. The term "heterocycle" includes "heteroaryl," which denotes a radical attached via a ring carbon of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(X) wherein each X is absent or 15 is H, 0, (C-C 4 )alkyl, phenyl or benzyl, as well as a radical of an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a benz-derivative or one derived by fusing a propylene, trimethylene, or tetramethylene diradical thereto. The term "enhancing" the activity of a p lactam antibiotic means improving or increasing the antibiotic activity of the 20 compared in a statistically measurable and significant manner with respect to the activity demonstrated by the compound in the absence of a compound of the invention. It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically 25 active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by 30 resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine p-lactamase 7 WO 00/63213 PCT/USOO/09929 inhibitory activity using the standard tests described herein, or using other similar tests which are well known in the art. Specific values listed below for radicals, substituents and ranges, are for illustration only; they do not exclude other defined values or other values 5 within defined ranges for the radicals and substituents. Specifically, (Cl-C 6 )alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl; (CI-CIO)alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, hexyl, heptyl, octyl, nonyl, or decyl; (C 3
-C
8 )cycloalkyl can be cyclopropyl, 10 cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; (CI-CIO)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, hexyloxy, heptyloxy, octyloxy, nonyloxy or decyloxy; (C C)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy; (C 2 -CIO)alkenyl can be vinyl, 1 15 propenyl, 2-propenyl, 1- butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1 octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1 nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8 20 nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7 decenyl, 8-decenyl, or 9-decenyl; (C 2 - C)alkenyl can be vinyl, 1-propenyl, 2 propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1- pentenyl, 2-pentenyl, 3-pentenyl, 4 pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, or 5-hexenyl; (C 2 CIo)alkynyl can be ethynyl, 1-propynyl, 2-propynyl, 1- butynyl, 2-butynyl, 3 25 butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1- hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-heptynyl, 2-heptynyl, 3-heptynyl, 4 heptynyl, 5-heptynyl, 6-heptynyl, 1-octynyl, 2-octynyl, 3-octynyl, 4-octynyl, 5 octynyl, 6-octynyl, 7-octynyl, 1-nonynyl, 2-nonynyl, 3-nonynyl, 4-nonynyl, 5 nonynyl, 6-nonynyl, 7-nonynyl, 8-nonynyl, 1-decynyl, 2-decynyl, 3-decynyl, 4 30 decynyl, 5-decynyl, 6-decynyl, 7-decynyl, 8-decynyl, or 9-decynyl; (C 2 C)alkynyl can be ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3 butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1- hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, or 5-hexynyl; (CI-CIO)alkanoyl can be acetyl, propanoyl, 8 WO 00/63213 PCT/USOO/09929 butanoyl, pentanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, or decanoyl; (Cl C)alkanoyl can be acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl; (C 1 C 10 )alkoxycarbonyl can be methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, hexyloxycarbonyl, 5 heptyloxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl or decyloxycarbonyl; (CI-CIO)alkanoyloxy can be formyloxy, acetoxy, propanoyloxy, butanoyloxy, isobutanoyloxy, pentanoyloxy, hexanoyloxy, heptanoyloxy, octanoyloxy, nonanoyloxy, or decanoyloxy; (C 1 - C 6 )alkanoyloxy can be formyloxy, acetoxy, propanoyloxy, butanoyloxy, isobutanoyloxy, pentanoyloxy, or hexanoyloxy; 10 halo(C-C 6 )alkanoyloxy can be iodoacetoxy, bromoacetoxy, chloroacetoxy, fluoroacetoxy, trifluoroacetoxy, 3-chloropropanoyloxy, 3-fluoropropanoyloxy, perfluoropropanoyloxy, or 3,3,3-trifluoropropanoyloxy; aryl can be phenyl, indenyl, or naphthyl; heterocycle can be triazolyl, triazinyl, oxazoyl, isoxazolyl, oxazolidinoyl, isoxazolidinoyl, thiazolyl, isothiazoyl, pyrazolyl, imidazolyl, 15 pyrrolyl, pyrazinyl, pyridinyl, morpholinyl, quinolinyl, isoquinolinyl, indolyl, pyrimidinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, or piperazinyl; and heteroaryl can be furyl, imidazolyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, thiazolyl, isothiazoyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl, 1 methyl-1H-tetrazol-5-yl, pyridyl, (or its N-oxide), thienyl, pyrimidinyl (or its N 20 oxide), indolyl, isoquinolyl (or its N-oxide) or quinolyl (or its N-oxide). Specifically, R, is aryl, heterocycle, or -COORa. Specifically, R, is 2-pyridyl, or -COORa. Specifically, R 2 is hydrogen. Specifically, R 3 is hydrogen, carboxy, or -CH 2 M wherein M is 25 hydrogen, halo, hydroxy, (C 3
-C
8 )cycloalkyl, (C 1 -C)alkoxy, aryloxy, aryl(Cl CIO)alkoxy, mercapto, (CI-CIO)alkylthio, arylthio, heterocycle, (heterocycle)thio, (CI-CIO)alkanoylthio, aminocarbonyloxy, or NRbR.. More specifically, M is hydrogen, halo, (CI-C 1 O)alkanoyloxy, or heterocycle. Specifically, R 3 is acetoxymethyl, phenylacetoxymethyl, (3,4 30 dihydroxyphenyl)acetoxymethyl, chloromethyl, formyl, or chloroacetoxymethyl. Specifically, R 3 is hydrogen, methyl, acetoxymethyl, or 1-methyl 1H-tetrazol-5-ylthiomethyl. 9 WO 00/63213 PCT/USOO/09929 Specifically, R 3 is vinyl, optionally substituted at the 2-position with halo, cyano, -COORa, trifluoromethyl, formal, (C 3 -C)cycloalkyl, (C 2 C)alkenyl, (C 2
-C
6 )alkynyl, heterocycle, or NRbRc; Specifically, R 3 is vinyl, optionally substituted at the 2-position 5 with cyano, -COORa, (C 2
-C
6 )alkenyl, or heteroaryl. Specifically, A is sulfonyl (-SO 2 -). Specifically, R 7 is aryl, heterocycle, or -COORe. Specifically, R 7 is 2-pyridyl, or -COORe. Specifically, R, is hydrogen. 10 Specifically, R and Rk are each independently hydrogen, cyano, COORe, (C-CIO)alkenyl, or heteroaryl. More specifically R, is carboxy, 2-pyridyl, tert-butoxycarbonyl, or methoxycarbonyl. More specifically, R 3 is 2-cyanovinyl, 2-(methoxycarbonyl)vinyl, 15 2- (2-pyridyl-N-oxide)vinyl, or 1,3-butadienyl. More specifically, RS and R 6 are each individually hydrogen. More specifically, R, and R 6 are each individually methylthio. More specifically, R and Rk are each independently hydrogen, cyano, 2-(methoxycarbonyl), 2-pyridyl-N-oxide, or vinyl. 20 A specific compound is a compound of formula I wherein A is sulfonyl (-SO 2 -); R, is 2-pyridyl, carboxy or tert-butoxycarbonyl; R 2 is hydrogen; R 3 is hydrogen, methyl, acetoxymethyl or 1-methyl-1H-tetrazol-5 ylthiomethyl; and R, and R 6 are the same and are each hydrogen or thiomethyl; or a pharmaceutically acceptable salt thereof 25 A specific compound is a compound of formula IV wherein A is sulfonyl (-SO 2 -); R 7 is 2-pyridyl, carboxy or tert-butoxycarbonyl; R, is hydrogen; and R 9 is 2-cyanovinyl, 2-(methoxycarbonyl)vinyl, 2-(2'-pyridyl-N oxide)vinyl, or 1,3-butadienyl; or a pharmaceutically acceptable salt thereof. A preferred compound of formula I or IV is a pharmaceutically 30 acceptable salt formed from a carboxylic acid of formula I or IV wherein R 4 or Rio is hydrogen. Most preferred is a salt wherein R 4 or R 1 0 been replaced with a sodium or potassium ion. The term pharmaceutically acceptable salts also includes poly salts (e.g. di- or tri-salts) of a compound of formula I or IV, 10 WO 00/63213 PCT/USOO/09929 particularly a dicarboxylic acid salt of a compound of formula I wherein R, is carboxy and R 4 is hydrogen, or a dicarboxylic acid salt of a compound of formula IV wherein R 7 is carboxy and Rio is hydrogen Processes and novel intermediates useful for preparing 5 compounds of formula I and IV are provided as further embodiments of the invention and are illustrated by the following procedures in which the meanings of the generic radicals are as given above unless otherwise qualified. Additional compounds of the present invention, processes of making compounds of the present invention, and/or intermediates of compounds of the present invention 10 are disclosed in Buynak et al., Bioorg. Med. Chem. Lett., 2000, 10 (2000) 4211 and Buynak et al., Bioorg. Med. Chem. Lett., 2000, 10 (2000) 4215. Pharmaceutically acceptable salts of compounds of formula I wherein R 4 has been replaced with a pharmaceutically acceptable cation (e.g. a sodium or potassium ion) can conveniently be prepared from a corresponding 15 compound of formula I wherein R 4 is hydrogen, by reaction with a suitable base, for example, as disclosed in Example 1 hereinbelow. Pharmaceutically acceptable salts of compounds of formula IV wherein RIO has been replaced with a pharmaceutically acceptable cation (e.g. a sodium or potassium ion) can conveniently be prepared from a corresponding 20 compound of formula IV wherein RIO is hydrogen, by reaction with a suitable base. A useful intermediate for preparing a compound of formula I or IV, wherein R 4 or RIO is hydrogen, is a corresponding compound wherein R 4 or Rio has been replaced with a suitable removable carboxy protecting group. Such 25 protecting groups are well known in the art, for example, see Greene, T.W.; Wutz, P.G.M. "Protecting Groups In Organic Synthesis" second edition, 1991, New York, John Wiley & Sons, Inc. Preferred protecting groups include (C, CIO)alkyl, (C 2 - CI 0 )alkenyl, (C 3
-C
8 )cycloalkyl, (C 2
-C
1 o)alkynyl, aryl, benzyl, or benzhydryl. Thus the invention provides compounds of formula I wherein RI, 30 R 2 , R 3 , R 5 , and R 6 have any of the values, specific values, or preferred values defined herein, and wherein R 4 is (CI-CIO)alkyl, (C 2 -CIO)alkenyl, (C 3 C 8 )cycloalkyl, (C 2 -CIO)alkynyl, aryl, benzyl, or benzhydryl. The invention also provides compounds of formula IV wherein R 7 , R 8 , and R 9 have any of the 11 WO 00/63213 PCT/US0O/09929 values, specific values, or preferred values defined herein, and wherein RIO is (CI-CIO)alkyl, (C 2 -CIO)alkenyl, (C 3
-C
8 )cycloalkyl, (C 2 - CIO)alkynyl, aryl, benzyl, and benzhydryl. Compounds of formula (I) can be prepared as shown in Figure I 5 by esterifying 7-aminocephalosporanic acid (commercially available from Aldrich) with diphenyldiazomethane to produce benzhydyl 7 aminocephalosporinate compound 1. Treatment with isoamyl nitrite in the presence of a catalytic amount of TFA at room temperature gives the corresponding diazo compound which is treated directly with propyleneoxide 10 and a catalytic amount of rhodium(II)octanoate dimer in benzene to give the corresponding benzhydryl 7-oxocephalosporinate compound 2. The degree of purity can be enhanced by substituting isoamylnitrite with isopropylnitrite and rhodium(II)acetate with rhodium(II)octonate. 7-Alkylidenecephalosporinates 3 can be prepared by treating 15 benzhydryl 7-oxocephalosporinate with the requisite Wittig Reagent. Oxidation of the resulting compound for example with an excess amount of 70% m-CPBA in methylene chloride and phosphate 6.4 buffer, gives the corresponding sulfone 4 that can be treated with Eschenmoser's salt in acetonitrile to give ester 5. Hydrolysis of the ester followed by salt formation under standard conditions, for 20 example, as illustrated in the Examples hereinbelow and in Figure 2, gives a compound 6. The invention also provides intermediates of formulae 2, 3, 4, and 5, wherein R 1 , R 2 , R 3 , R 5 , and R 6 have any of the values, specific values, or preferred values defined herein, and wherein "Bhl" is diphenylmethyl or is 25 another suitable carboxy protecting group such as for example (CI-CIO)alkyl, (C 2 C 1 O)alkenyl, (C 3 - Cg)cycloalkyl, (C 2 -CIO)alkynyl, aryl, or benzyl, that are useful to prepare compounds of formula I. As illustrated in Figure 3, compounds of formula IV (e.g. wherein
R
7 is 2-pyridyl and R 8 is hydrogen) can be prepared from compound 7, which is 30 available from 2, using procedures similar to those described by J. D. Buynak et. al., J. Med. Chem. 38, 1022-1034, 1995. Thus, 7 is isomerized to a 1:3 mixture of 7 and 8, respectively. Compound 8 is separated and hydrolyzed to alcohol 9, which is oxidized to provide aldehyde 10. Reaction of 10 with a series of ylides 12 WO 00/63213 PCT/USOO/09929 provides compounds 11a through 1f. Compound 10 can also be condensed with nitromethane to produce nitroalkene 11h (Figure 4), or can be reacted with hydroxylamine hydrochloride to produce oxime 14 (Figure 4), which itself can be reacted with thionyl chloride to generate nitrile 17. Oxidation of compounds 5 11a-11f, 11h, 14, and 17 yields the corresponding sulfones. Compound 12e can also be reacted with Eschenmoser's salt to generate sulfone 20 (Figure 4). Hydrolysis of the esters 12a-12f, 12h, 15, 18, and 20 (e.g. with trifluoroacetic acid (TFA) in anisole) yields the carboxylate salts 13a-13f, 13h, 16, 19, and 21, which are active as p-lactamase inhibitors. Compound 13g was prepared by 10 hydrolysis of compound 12e. A compound that is particularly useful for preparing a compound of formula IV is an aldehyde of formula V: 15 R 8
-
1 A 0 CHO
COOR
10 (V) 20 wherein R 7 , R 8 , RIO, and A have any of the values, specific values, or preferred values described herein. Compounds of formula I wherein R, and R 2 are alkoxy or alkene may be synthesized using an appropriate Wittig reagent R 1
R
2
C=PP
3 . The Wittig 25 reagents ROCH=PPh 3 , H 2 C=CH-CH=PPh 3 , and similar reagents may also be used to make the 7-alkoxymethylene and 7-alkenylmethylene compounds, respectively. The 7-alkanoylmethylene species may be made by forming the vinyl anion and reacting it with a desirable alkanoyl halide. The vinyl anion may 30 be made by a standard lithium-halogen (or magnesium-halogen) exchange reaction, for example, reaction of compound 4a with methyl lithium. The lithium vinyl group may then be functionalized by reaction with an alkoxycarbonyl chloride. 13 WO 00/63213 PCT/USO0/09929 2-or 7-Carboxylmethylene compounds (RI, R2, R5, or R6 = COOH) may be formed by hydrolysis of a corresponding ester, preferably, the corresponding t-butyl ester. Compounds wherein R 3 is a halogen may be formed by 5 displacement of an acetoxy group with ethyl xanthate (EtOCS 2 K), followed by Raney-Nickel desulfurization (H 2 /Ra-Ni) to give the exocyclic alkene, which can be ozonized to the 3-hydroxy cephem. Reaction of the hydroxy compound with a halogenating reagent gives the 3-halo species. For example, PCl 5 may be used to convert the 3-OH group into a 3-Cl group. 10 Compounds wherein R 3 is a hydrogen may be formed by reduction of the aforementioned 3-hydroxy cephem to the corresponding 3 hydroxy cepham with sodium borohydride. Subsequent treatment with methanesulfonyl chloride in the presence of triethylamine results in elimination of the hydroxyl group generating the compound in which R 3 is hydrogen. 15 Compounds wherein R 3 is methyl, can be obtained from the commercially available starting material 7-amino-3-desacetoxycephalosporin using a sequence similar to that illustrated in Figure 1. Compounds wherein R 3 is 3-hydroxymethyl may be obtained by hydrolysis of a corresponding acetoxy group (e.g. with NaOH or an appropriate 20 enzyme). Compounds wherein R 3 is halomethyl may be formed by reaction of a corresponding 3-hydroxymethyl compound with a halogenating reagent. For example, PCl 5 may be used to form the 3-chloromethyl species. Compounds wherein R 3 is alkoxymethyl, aryloxymethyl, or 25 arylalkoxymethyl may be obtained by reaction of the corresponding 3 hydroxymethyl compound with tosyl chloride and displacement of the resultant tosylate with an oxide. For example, sodium methoxide may be used to obtain the 3-methoxymethyl species. Compounds wherein R 3 is mercaptomethyl may be formed by 30 reaction of a corresponding 3-chloromethyl compound with sodium sulfhydride (NaSH). This compound may further be derivatized with an alkylhalide to form a alkylthio group, or an acylchloride to form an acylthio group, for example, as 14 WO 00/63213 PCTIUSOO/09929 described in Jerry March "Advanced Organic Chemistry" John Wiley & Sons, 4 ed.1992, 407. Compounds wherein R 3 is aminomethyl may be formed by the Gabriel Synthesis, i.e., reaction of the corresponding 3-chloromethyl compound 5 with potassium phthalimide followed by hydrolysis of the product with acid to yield the 3-aminomethyl compound. A compound of formula I wherein R 3 is hydroxymethyl may also be prepared from a corresponding compound of formula I wherein R 3 is chloroacetoxymethyl by treatment with thiourea in the presence of a suitable 10 base, such as for example, pyridine (T. Greene, P. Wutz "Protective Groups in Organic Synthesis, Second Edition; John Wiley and Sons, Inc.; New York, 1991, p. 92). A compound of formula I wherein R 3 is cyanomethyl can be prepared from a corresponding compound of formula I wherein R 3 is halomethyl 15 using techniques that are well known in the art, for example techniques such as those described in Jerry March "Advanced Organic Chemistry" John Wiley & Sons, 4 ed.1992, 482. A compound of formula I wherein R 3 is -CH 2 NRbRe can be prepared from a corresponding compound of formula I wherein R 3 is -CH 2 (halo) 20 using techniques that are well known in the art, for example techniques such as those described in Jerry March "Advanced Organic Chemistry" John Wiley & Sons, 4 ed.1992, 411-413, 425-427. A compound of formula I wherein R 3 is formyl can be prepared from a corresponding compound of formula I wherein R 3 is hydroxymethyl by 25 oxidation, using techniques which are well known in the art. A compound of formula I wherein R 3 is a 1-alkenyl substituent can generally be prepared from a corresponding compound of formula I wherein
R
3 is formyl, by reaction with the requisite ylide or stabilized ylide, using techniques which are well known in the art. 30 A compound of formula I wherein R 3 is cyanatomethyl can be prepared from a corresponding compound of formula I wherein R 3 is hydroxymethyl by reaction with a cyanogen halide using techniques that are well 15 WO 00/63213 PCT/US00/09929 known in the art, for example techniques such as those described in Jerry March "Advanced Organic Chemistry" John Wiley & Sons, 4 ed.1992, 387. Compounds wherein R 3 is aminocarbonylmethyl can be formed by displacement of the corresponding tosylate with cyanide, e.g., KCN, followed 5 by hydrolysis of the resulting nitrile to the amide. A compound of formula I or IV wherein A is sulfonyl (-SO 2 -) can be prepared by oxidation of a corresponding compound of formula I or IV wherein A is thio (-S-), for example, by using meta-chloroperbenzoic acid (mCPBA). 10 A compound of formula I or IV wherein A is sulfinyl (-SO-) can be prepared by oxidation of a corresponding compound of formula I or IV wherein A is thio (-S-), using one equivalent of an acceptable oxidizing agent, for example, mCPBA. Another useful intermediate for the preparation of a compound of 15 the invention is an ylide, for example a ylide of formula RR 2 C=PPh 3 ,
R
5
R
6 C=PPh 3 , or R RkC=PPh 3 . Ylides can be prepared using techniques that are well known in the art, for example techniques such as those described in Jerry March "Advanced Organic Chemistry" John Wiley & Sons, 4 ed.1992, 956-963. Suitable ylides are also disclosed in U.S. Patent Number 5,597,817, issued 20 January 29, 1997; and U.S. Patent Number 5,629,306, issued May 13, 1997. Compounds of formula I and IV wherein A is -S- or -SO- are particularly useful as intermediates for preparing the corresponding compounds of formula I or IV wherein A is -S02-. Many of the starting materials employed in the synthetic methods 25 described above are commercially available or are reported in the scientific literature. It may be desirable to optionally use a protecting group during all or portions of the above described synthetic procedures. Such protecting groups and methods for their introduction and removal are well known in the art. See Greene, T.W.; Wutz, P.G.M. "Protecting Groups In Organic Synthesis" second 30 edition, 1991, New York, John Wiley & Sons, Inc. In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid 16 WO 00/63213 PCT/USOO/09929 addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, a-ketoglutarate, and a-glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, 5 nitrate, bicarbonate, and carbonate salts. Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example, by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or 10 alkaline earth metal (for example, calcium) salts of carboxylic acids can also be made. The compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to a selected route of administration, i.e., by oral, 15 parenteral, intravenous, intramuscular, topical, or subcutaneous routes. Thus, the present compounds may be systemically administered, e.g., orally, in combination with a phannaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be 20 incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The 25 percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained. The tablets, troches, pills, capsules, and the like may also contain 30 the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame 17 WO 00/63213 PCT/USOO/09929 or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to 5 otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in 10 preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices. The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or 15 its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. 20 The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be 25 sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can 30 be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, 18 WO 00/63213 PCT/USO0/09929 phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum 5 monostearate and gelatin. Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile 10 injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions. For topical administration, the present compounds may be applied 15 in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid. Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid 20 carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent 25 pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers. Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, 30 soaps, and the like, for application directly to the skin of the user. Examples of useful dermatological compositions which can be used to deliver the compounds of the invention to the skin are disclosed in 19 WO 00/63213 PCT/USOO/09929 Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508). The present compositions may also be prepared in suitable forms for absorption through the mucous membranes of the nose and throat or 5 bronchial tissues and may conveniently take the form of powder or liquid sprays or inhalants, lozenges, throat paints, etc. For medication of the eyes or ears, the preparations may be presented as individual capsules, in liquid or semi-solid form, or may be used as drops, etc. Topical applications may be formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints, powders, 10 etc. For veterinary medicine, the composition may, for example, be formulated as an intramammary preparation in either long acting or quick-release bases. Useful dosages of the compounds of the invention can be 15 determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949. Generally, the concentration of the compound(s) of the invention 20 in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%. The compositions per unit dosage, whether liquid or solid may 25 contain from 0.1% to 99% of active material (the present 7-vinylidene cephalosporins and optional antibiotic), the preferred range being from about 10 60%. The composition will generally contain from about 15 mg to about 1500 mg by weight of active ingredient based upon the total weight of the composition; however, in general, it is preferable to employ a dosage amount in 30 the range of from about 250 mg to 1000 mg. In parenteral administration the unit dosage is usually the pure compound in a slightly acidified sterile water solution or in the form of a soluble powder intended for solution. Single dosages 20 WO 00/63213 PCT/US0O/09929 for injection, infusion or ingestion may be administered, i.e., 1-3 times daily, to yield levels of about 0.5 - 50 mg/kg, for adults. The invention provides a pharmaceutical composition, comprising an effective amount of a compound of formula I or IV as described hereinabove; 5 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of a compound of formula I or IV as described hereinabove; or a pharmaceutically acceptable salt thereof; a p-lactam antibiotic; and a pharmaceutically acceptable carrier. The present compositions are preferably 10 presented in a form suitable for absorption by the gastro-intestinal tract. Any p-lactam antibiotic is suitable for use in the pharmaceutical composition of the invention. p-lactam antibiotics which are well known in the art include those disclosed by R.B. Morin and M. Gorin, M.Eds.; Academic Press, New York, 1982; vol. 1-3. Preferred p-lactam antibiotics, suitable for use 15 in the pharmaceutical composition of the invention, include p-lactam antibiotics which are preferentially deactivated by Class A and Class C p-lactamase enzymes, for example, amoxicillin, piperacillin, ampicillin, ceftizoxime, cefotaxime, cefuroxime, cephalexin, cefaclor, cephaloridine, and ceftazidime. The ability of a compound of the invention to function as a P 20 lactamase inhibitor can be demonstrated using the test described below, or using other tests which are well known in the art. Representative compounds of formula I were evaluated as inhibitors of the Class C p-lactamase of Enterobacter cloacae P- 99, a cephalosporinase, and TEM-1, a penicillinase, by relative IC 50 analysis. The IC 50 value represents the concentration of inhibitor 25 required to effect a 50% loss of activity of free enzyme. The IC 50 value of each compound was determined as follows. Following a 10 minute incubation of a dilute solution of enzyme (2.56 nM) and inhibitor (<0.64 mM), a 50 mL aliquot of this incubation mixture was then further diluted into 1 mL nitrocefin solution, and the rate of hydrolysis was measured during a 1 minute period by monitoring 30 the absorbance of nitrocefin as a function of time. In addition, the IC 5 0 values of tazobactam were determined as relative controls. The data is presented in Table 1 below for compounds of the formulae I, II, and III. 21 WO 00/63213 PCT/USOO/09929 TABLE 1
IC
50 Values for Inhibition of P-lactam22ase (gM) Derived from P-99 or TEM-1 (relative to tazobactum standard) 5 No. eype R1 R2 R3 R4 R5 R6 P-99 TEM-1 tazo Na 74.5 0.243 6a I 2-p H CHOAc Na H H 0.165 99.2 6b I CO,-t-Bu H CH,OAc Na H H 1.55 0.932 6c I 2- H CH, Na H H 0.039 91.1 10 6d I CO,-t-Bu H CH, Na H H 48.6 56.5 6f I CO,-t-Bu H CHS(CNH) Na H H 2.38 1.13 6 I 2- H CH, Na SCH SCH, 0.51 172.8 6h I CONa H CH,OAc Na H H 2.49 498 6i I CONa H CH, Na H H 36.8 277 15 II 2- H CH, Na 6.10 377 II 2- H CH,OAc Na 1.35 14.4 II C0 2 -t-Bu H CH 3 Na 199 111.2 II CO,-t-Bu H CH,OAc Na II CO,-t-Bu H CHS(CN4H,) Na 112 0.123 20 III CH,OAc Na H H 315 >2000 Compounds of formulae II and III are provided for comparison purposes. Compounds of formula I generally possess activity as p-lactamase 25 inhibitors, and, thus, are useful as therapeutic agents and as pharmacological tools as described herein. Compounds of formulae II and III are generally less effective against P-99 than corresponding compounds of formula I. In general, compounds of formula I are more potent toward P-99 than is tazobactam, showing a 1 to 2000 fold increase in activity. Many compounds of formula I Ri 02 R 5 02 H H 2 O HR H R H 00 303 COOR4 COOR4
COOR
4 30 also show activity toward TEM-1. Representative compounds of formula IV were also evaluated as inhibitors of the Class C p-lactamase of Enterobacter cloacae P-99, a cephalosporinase, and TEM-1, a penicillinase, by relative IC 50 analysis using a 22 WO 00/63213 PCT/USOO/09929 procedure similar to that described above. The data is presented in Table 2 below. TABLE 2 5 IC 50 Values (gM) for Inhibition of p-lactamase Derived from P-99 or TEM-1 No P-99 TEM 1 13a 0.01 2.7 13b 0.2 0.02 10 13c 0.6 0.006 13e 1.48 13f 0.2 0.02 13 0.31 2.52 19 0.029 2.34 15 The present p-lactamase inhibitors of formulae I and IV are particularly useful in the treatment of infections associated with Enterobacter, Citrobacter, and Serratia. These bacteria have the ability to attach to the epithelial cells of the bladder or kidney (causing urinary tract infections) and are 20 resistant to multiple antibiotics including amoxicillin and ampicillin. The present p-lactamase inhibitors of formula I are also be useful in the treatment of infections associated with highly resistant Pneumococci. Such diseases include otitis media, sinusitis, meningitis (both in children and adults), bacteremia, and septic arthritis. Resistant pneumococcal strains have 25 surfaced in many parts of the world. For example, in Hungary, 58% of S. pneumoniae are resistant to penicillin, and 70% of children who are colonized with S. pneumoniae carry resistant strains that are also resistant to tetracycline, erythromycin, trimethoprin/sulfamethoxazole (TMP/SMX), and 30% resistant to chloramphenicol. Klebsiella pneumoniae (resistant via the production of P 30 lactamase) have caused hospital outbreaks of wound infection and septicemia. Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof. 23 WO 00/63213 PCT/USOO/09929 EXAMPLES Example 1: Sodium salt of 7-[(Z)-(2'-pyridyl)methylenel-2 (exomethylidene) cephalosporanic acid sulfone (6a). 5 To a solution of ester 5a (1.0 g, 1.43 mmol) in anisole at 0 'C was added trifluoroacetic acid ('TFA") and the reaction mixture was stirred for 10 minutes. TFA and anisole were removed in vacuo and the residue was dissolved in EtOAc and extracted into aqueous sodium bicarbonate. The aqueous layer was loaded 10 onto reverse phase column and eluted with 5% ethanol/water to give compound 6a (0.58 g, 79%). 'H NMR (400 MHZ, D 2 0): 8 8.41 (d, J = 4.53 Hz), 7.68 (t, J = 7.84 Hz, 1H), 7.37-7.39 (m, 1H), 7.35 (s, 1H), 7.23-7.26 (m, 1H), 6.33 (s, 1H), 6.13 (s, 1H), 6.03 (s, 1H), 4.94 (s, J = 12.73 Hz, 1H), 4.58 (d, J = 12.8 Hz, 1H), 1.86 (s, 3H). 15 The intermediate ester 5a was prepared as follows. a. Benzhydryl 7-Oxocephalosporinate (2a). To a solution of benzhydryl 7-aminocephalosporinate (0.5 g, .15 mmol) (which can be prepared in one step 20 from the commercially available 7-aminocephalosporanic acid according to procedures described in Buynak et. al. J Am. Chem. Soc. 116, 10955-10965, 1994 ) in ethyl acetate (5 mL) were added isopropyl nitrite (0.38 mL, 1.71 mmol, 40% solution in CH 2 Cl 2 ) and trifluoroacetic acid (6.5 mg, 0.05 mmol) and the reaction was allowed to stir for 1 hour at room temperature. The reaction 25 mixture was concentrated under reduced pressure and redissolved in benzene (5 mL). To this solution was added propylene oxide (6.7 g, 0.114 mol) followed by rhodium octanoate dimer (5 mg) and the reaction was stirred for 15 minutes (until evolution of nitrogen ceases). Volatiles were removed to produce the title compound 2a (0.5 g, quantitative, 90% pure); IR (CHC1 3 ) 3005, 1830, 1790, 30 1740 cm- 1 ; 'H NMR (CDCl 3 ) 8 7.39 (10 H, m), 7.05 (1 H, s), 5.32 (1 H, s), 5.07 (1 H, d, A of ABq, J = 13.9 Hz), 4.85 (1 H, d, B of ABq, J = 14.0 Hz), 3.64 (1 H, d, A of ABq, J = 18.5 Hz), 3.44 (1 H, d, B of ABq, J = 18.6 Hz), 2.05 (3 H, s); 3 C NMR (CDCl 3 ) 188.4 (s), 170.3 (s), 160.1 (s), 158.7 (s), 138.8 (s), 138.6 (s), 24 WO 00/63213 PCTIUSOO/09929 128.4, 128.2, 128.1, 127.7, 126.9, 126.2, 80.1 (d), 65.8 (d), 62.6 (t), 27.7 (t), 20.4 (q). b. Benzhydryl 7-[(Z)-(2'-pyridyl)methylene]cephalosporinate (3a). To a 5 solution of 2-picolyl chloride hydrochloride (13.1 g, 80 mmol) in water (20 mL) was added into potassium carbonate (11.0 g, 80 mmol). After the carbonate was completely dissolved, the solution was extracted with ether (3x1OmL). The combined organic layers were washed with saturated NaCl solution (1 x 30 mL), dried (Na 2
SO
4 ) and concentrated to give picolyl chloride (9.2 g, 90%). Picolyl 10 chloride (8.9 g, 70 mmol), triphenylphosphine (18.3 g, 70 mmol) and 1,4 dioxane (30 mL) were mixed and refluxed for 24 hours. The reaction mixture was washed with ether (2 x 30 mL) and the remaining solid was dried in vacuo to give a white solid (25.5 g, 94%). A mixture of 2 picolyltriphenylphosphonium chloride (5.8 g, 15 mmol) and sodium amide (0.58 15 g, 15 mmol) in THF (15 mL) was stirred at room temperature for 30 minutes. The resulting brown suspension was cooled to -78 'C and a solution of benzhydryl 7-oxocephalosporinate 2a (6.6g, 15 mmol) in THF (15 mL) was added in one portion and the mixture was stirred at -78 'C for 15 minutes. The reaction was quenched by the addition of saturated ammonium chloride solution 20 (10 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with water (2 x 40 mL), dried over MgSO 4 , concentrated and purified by column chromatography to obtain a 3a as a yellow solid (2.9 g, 38%). Rf= 0.28 in 2% EtOAc in CH 2 Cl 2 ; mp 181-183'C; IR (CHCl 3 ) 3060, 1810, 1750 cm-'; 'H NMR (CDCl 3 ) 8 8.68 (1H, d), 7.72 (1H, t), 7.35(12H, m), 25 7.15 (1H, s), 7.10 (1H, s), 5.66 (1H, s), 4.96 (1H, d, A of ABq, 13 Hz), 4.73 (1H, d, B of ABq, J = 13 Hz), 3.63 (lH, d, A of ABq, J = 18 Hz), 3.63 (1H, D, B of ABq, J = 18 Hz), 2.01 (3H, s); 1 3 C NMR (CDCl 3 ) 6 170.3 (s), 161.0 (s), 160.2 (s), 151.6 (d), 150.1 (s), 140.6 (s), 139.3 (s), 139.1 (s), 136.6 (d), 128.3, 127.9, 127.8, 127.6, 127.2, 126.9, 125.8 (s), 123.9 (s), 123.5 (s), 79.5 (d), 63.0 (t), 58.5 30 (d), 28.0 (t), 20.5 (q); high-resolution mass spectrum for [C 29
H
2 4
N
2 0 5 SNa]*, i.e. [M+Na]*, m/z calcd 535.1304, found 535.1300. 25 WO 00/63213 PCT/USOO/09929 c. Benzhydryl 7-[(Z)-(2'-Pyridyl)methylene]cephalosporinate Sulfone (4a). To a solution of sulfide 3a (0.45 g, 0.88 mmol) in CH 2 Cl 2 (10 mL) and pH = 6.4 Buffer solution (10 mL) was added m-CPBA (85%, 0.71g, 3.52 mmol) in one portion. The mixture was stirred at room temperature for 30 minutes, and 5 then ether (50 mL) was added. After separating layers, the organic layers were washed with saturated NaHCO 3 (3 x 30 mL), dried (NaSO 4 ), concentrated and purified by column chromatography to yield a white solid (yield = 90%); Rf= 0.26 in 2% EtOAc in CH 2 C1 2 ; mp 120-122'C; IR (CHCl 3 ) 2975, 2950,1780,1720,1340,1130 cm1; 'H NMR (CDCl 3 ) 8 8.67 (1H, d), 7.71 (1H, t), 10 7.40 (13H, m), 7.00 (lH1, s), 5.91 (lH, s), 5.14 (lH, d, A of ABq, J = 14 Hz), 4.80 (1H, B of ABq, J = 14 Hz), 4.11 (1H, d, A of ABq, J = 18 Hz), 3.78 (1H, d, B of ABq, J = 18 Hz), 2.05 (3H, s); high-resolution mass spectrum for
[C
29
H
2 4
N
2 0 7 SNa]*, i.e. [M+Na]*, m/z calcd 567.1202, found 567.1198. 15 d. Benzhydryl 7-[(Z)-(2 "-pyridinyl)methylene]-2-(exomethylidene) cephalosporinate Sulfone (5a). To a solution of sulfone 4a (0.75 g, 1.37 mmol) in dry CH 3 CN (10 mL) at 0 'C was added Eschenmoser's salt (0.57 g, 3.06 mmol) and the reaction was stirred for 3 hours. CH 3 CN was then removed under reduced pressure and the reaction mixture was dissolved in CH 2 Cl 2 (30 mL) and 20 washed with water (2 x 30 mL) and brine. The organic layer was dried over Na 2
SO
4 and concentrated under reduced pressure to give 697 mg (91%) of 5a; 'H NMR (400 MHZ, CDC 3 ) 6 8.68 (d, J = 5.01 Hz, 1H), 7.73 (t, J = 5.99 Hz, 1H), 7.42-7.31 (m, 1OH), 7.05 (s, 1H), 6.67 (s, 1H), 6.16 (s, 1H), 6.04 (s, 1H), 5.20 (d, J = 12.95 Hz, 1H), 4.63 (d, J = 12.95 Hz), 1.95 (s, 3H). 25 Example 2: Sodium salt of 7-[(Z)-(tert-butoxycarbonyl)methylene]-2 (exomethylidene)cephalosporinate Sulfone (6b). To a solution of ester 5b (0.68 g, 1.16 mmol) in anisole (3.79 mL, 30 34.9 mmol) at 0 'C was added TFA (10.8 mL, 139 mmol) and the reaction mixture stirred for 10 minutes. TFA and anisole were removed in vacuo and the residue was dissolved in EtOAc and extracted into a solution of NaHCO 3 (0.146g/10 mL H 2 0). The aqueous layer was then loaded onto reverse phase 26 WO 00/63213 PCTIUSOO/09929 column chromatography and compound 6j eluted with water and the compound 6b eluted with 5% EtOH/water; 'H NMR (400 MHZ, D 2 0) 8 6.65 (s, 1H), 6.40 (s, 1H), 6.07 (s, 1H), 5.82 (s, 1H), 4.98 (d, J = 10.87 Hz, 2H), 1.89(s, 3H). 5 The intermediate ester 5b was prepared as follows. a. Benzhydryl 7-[(Z)-t-butoxycarbonylmethylenelcephalosporinate (3b). To a solution of benzhydryl 7-oxocephalosporinate 2a (4.0 g, 9.2 mmol) in anhydrous CH 2 Cl 2 (40mL) at -78 'C was added a solution of 10 methyl(triphenylphosphoranylidene)acetate (3.45 g, 9.15 mmol in 40 mL
CH
2 Cl 2 ). The mixture was then stirred at -78 'C for 30 minutes. Acetic acid (1 mL) was added to quench the reaction and the reaction mixture was concentrated and purified by column chromatography to give compound 3b as a pale yellow solid (55%); Rf= 0.52 in 2% EtOAc in CH 2 Cl 2 ; mp 48-50'C; IR (CHCl 3 ) 3050, 15 1780, 1730 cm-'; 'H NMR (CDCl 3 ) 5 7.36 (10H, m), 7.00 (1H, s), 6.39 (1H, s), 5.47 (1H, s), 5.00 (1H, d, A of ABq, J = 13.48 Hz), 4.77 (1H, d, B of ABq, J = 13.48 Hz), 3.62 (1H, d, A of ABq, J = 18 Hz), 3.38 (lH, d, B of ABq, J = 18 Hz), 2.02 (3H, s), 1.54 (9H, s); 1 3 C NMR (CDCl 3 ) 5 170.2 (s), 162.4 (s), 160.5 (s), 157.8 (s), 150.1, (s), 139.0 (s), 138.8 (s), 128.3, 128.0, 127.9, 127.5, 126.9, 125.0 20 (s), 119.9 (d), 82.9 (s), 79.7 (d), 62.8 (t), 57.5 (d), 28.0 (q), 27.9 (t), 20.4 (q). Anal. Calcd for C 29
H
29
NO
7 S: C, 65.05; H, 5.42; N, 2.62. Found: C, 64.50; H, 5.42, N, 2.62. b. Benzhydryl 7- [(Z)-(t-butoxycarbonyl)methylene] cephalosporanate 25 Sulfone (4b). This compound was prepared from the corresponding sulfide 3b using a procedure similar to that described in Example 1 sup-part c, to give a white solid (73%); Rf= 0.68 in 5% EtOAc in CH 2 Cl 2 ; mp 58-60'C; IR (CHCl 3 ) 3025, 1800, 1730, 1350, 1160 cm~1; 'H NMR (CDC 3 ) 57.36 (10H, m), 6.98 (1H, s), 6.59 (1H, s), 5.58 (1H, s), 5.14 (1H, d, A of ABq, J = 14 Hz), 4.80 (1H, 30 d, B of ABq, J = 14 Hz), 4.12 (1H, d, A of ABq, J = 18 Hz), 3.77 (1H, d, B of ABq, J = 18 Hz), 2.04 (3H, s), 1.52 (9H, s); "C NMR (CDCl 3 ) 5 170.0 (s), 161.5 (s), 159.4 (s), 157.1 (s), 142.3 (s), 138.6 (s), 138.5 (s), 128.8, 128.4, 128.3, 127.2, 127.0, 125.9 (s), 123.5 (d), 83.8 (s), 80.2 (d), 71.6 (d), 61.3 (t), 52.8 (t), 27 WO 00/63213 PCT/USOO/09929 27.6 (q), 20.2 (q); high-resolution mass spectrum for [C 2 9
H
29
NO
9 SNa]*, i.e. [M+Na]*, m/z calcd 590.1461, found 590.1447. c. Benzhydryl 7-[(Z)-(tert-butoxycarbonyl)methylene]-2 5 (exomethylidene) cephalosporinate Sulfone (5b). To a solution of sulfone 4b (0.7 g, 1.22 mmol) in dry CH 3 CN (10 mL) at 0 'C was added Eschenmoser's salt (0.45g, 2.43 mmol) and the reaction was stirred for 3 hours. CH 3 CN was then removed under reduced pressure and the reaction mixture was dissolved in CH 2 Cl 2 (20 mL) and 10 washed with water (2 x 30mL). The organic layer was dried over Na 2
SO
4 and concentrated under reduced pressure to give compound 5b (680 mg, 96%); 'H NMR (400 MHZ, CDCl 3 ) 5 7.41-7.25 (m, 10H), 7.0 (s, 1H), 6.71 (s, 1H), 6.6 (s, 1H), 6.2 (s, 1H), 5.6 (s, 1H), 5.26 (d, J = 13.0 Hz, 1H), 4.68 (d, J = 13 Hz, 1H), 1.56 (s, 3H). 15 Example 3: Sodium Salt of 7-[(Z)-(2 "-Pyridinyl)methylene]-3'-desacetoxy 2-(exomethylidene)cephalosporinate Sulfone (6c). To a solution of ester 5c (0.3 g, 0.597 mmol) in anisole (1.94 g, 20 64.5 mmol) at 0 'C was added TFA (8.17 g, 71.7 mmol) and the reaction stirred for 10 minutes. TFA and anisole were removed in vacuo and the residue was dissolved in ethyl acetate (10 mL). The compound was extracted into an aqueous solution of NaHCO 3 . The aqueous layer was loaded onto a column of the high porous polymer CHP20P (MitsubishI Chemical Corp., White Plains, 25 NY) eluted with 5% EtOH/water to give compound 6c (0.17 g, 80%); 'H NMR (400 MHZ, D 2 0) 6 8.55 (d, J = 5.2 Hz, 1H), 7.83 (t, J = 7.66 Hz, 1H), 7.61 (d, J = 7.63 Hz, 1H), 7.46 (s, 1H), 7.38-7.41 (m, 1H), 6.43 (s, 1H), 6.25 (s, 1H), 6.11 (s, 1H), 1.94 (s, 3H). 30 The intermediate 5c was prepared as follows. a. Benzhydryl 7-Oxo-3'-(desacetoxy)cephalosporinate (2b). To a solution of benzhydryl 7-amino-3'-(desacetoxy)cephalosporinate (15 g, 39.5 28 WO 00/63213 PCT/USOO/09929 mmol) in ethyl acetate (300 mL) were added isopropyl nitrite (13.3 mL, 59.2 mmol, 40% solution in CH 2 C1 2 ) and trifluoroacetic acid (0.13 g, 1.18 mmol) and the reaction was allowed to stir for 1 hour at room temperature. The reaction mixture was concentrated under reduced pressure and redissolved in benzene (75 5 mL). To this solution was added propylene oxide (150 mL) followed by rhodium octanoate dimer (100 mg) and the reaction was stirred for 15 n-tin (until evolution of nitrogen ceases). Volatiles were removed to produce compound 2b (15 g, quantitative, >90% pure); 'H NMR (CDCl 3 ) 6 7.97-7.25 (10 H, in), 6.99 (1 H, s), 5.29 (1 H, s), 3.47 (1 H, d, A of ABq, J = 17.9 Hz), 3.29 (1 H, d, B of 10 ABq, J= 17.9 Hz), 2.18 (3 H, s). b. Benzhydryl 7-(Z)-[(2'-Pyridyl)methylene]-3'-desacetoxy cephalosporinate (3c). To a solution of potassium t-butoxide (3.16 g, 28.3 mmol) in dry THF (40 mL) was added (2'-picolinyl)triphenylphosphonium 15 chloride (11.6 g, 29 mmol) and the reaction was stirred for 60 minutes. This freshly generated ylide was added to a cold (-78 C) solution of ketone 2b via cannula and the reaction was stirred for 45 minutes at the same temperature. The reaction mixture was quenched with a saturated solution of NH 4 C1 (50 mL) and extracted with ether (250 mL). The organic layer was then dried over Na 2
SO
4 20 and concentrated under reduced pressure to give 3c (3.6 g ). 'H NMR (400 MHZ, CDCl 3 ) 8 8.67 (d, 1H), 7.29 (d, 1H), 7.52 (2H), 7.50-7.25 (m, 10H), 7.10 (s, 1H), 6.9 (s, 1H), 5.65 (s, 1H), 3.47 (d, J = 18.0 Hz, 1H), 3.19 (d, J = 18.0 Hz, 1H), 2.10 (s, 3H). 25 c. Benzhydryl 7-(Z)-[(2'-Pyridinyl)methylene]-3'-(desacetoxy) cephalosporinate Sulfone (4c). To a solution of sulfide 3c (2 g, 4.39 mmol) in
CH
2 C1 2 (25 mL) was added m-CPBA (70%) (3g, 17.6 mmol) and phosphate 6.4 buffer (25 mL) and the resulting solution was stirred for 1 hour. The reaction mixture was diluted with CH 2 Cl 2 and the organic layer was washed with Na 2
SO
3 30 (2 x 30 mL) followed by NaHCO 3 (2 x 25 mL), extracted with CH 2 Cl 2 (50 mL), dried over sodium sulphate, concentrated under reduced pressure, and purified by silica gel column chromatography to give 4c (7 1%); 'H NMR (400 MHZ, 29 WO 00/63213 PCT/USOO/09929 CDCl 3 ) 6 8.67 (d, 1H), 7.71 (d, 1H), 7.49 (2H), 7.39-7.25 (m, 1OH), 6.9 (s, 1H), 5.7 (s, 1H), 3.86 (d, J = 16.6 Hz, 1H), 3.79 (d, J = 16.6 Hz, 1H), 2.2 (s, 3H). d. Benzhydryl 7-[(Z)-(2"-pyridinyl)methylene]-3'-desacetoxy-2 5 (exomethylidene)cephalosporinate Sulfone (5c). To a solution of sulfone 4c (0.75 g, 1.53 mmol) in dry CH 3 CN (10 mL) at 0 'C was added Eschenmoser's salt (0.57 g, 3.06 mmol) and the reaction was stirred for 3 hours. CH 3 CN was then removed under reduced pressure and the reaction mixture was dissolved in
CH
2 Cl 2 (30 mL) and washed with water (2 x 30mL) and brine. The organic layer 10 was dried over Na 2
SO
4 and concentrated under reduced pressure to give compound 5c (720 mg, 93%); 'H NMR (400 MHZ, CDCl 3 ) 6 8.69 (d, J = 0.88 Hz, 1H), 7.73 (t, J = 8 Hz, 1H), 7.47-7.31 (m, 12H), 7.04 (s, 1H), 6.67 (s, 1H), 6.05 (s, 1H), 6.01 (s, 1H), 2.07 (s, 3H). 15 Example 4: Sodium salt of 7-[(Z)-(tert-butoxycarbonyl)methylene]-3' desacetoxy-2 (exomethylidene)cephalosporinate Sulfone (6d). To a solution of ester 5d (0.3 g, 0.572 mmol) in anisole (1.86 mL, 17.2 mmol) at 0 0 C was added TFA (2.65 mL, 34.3 mmol) and the reaction 20 stirred for 10 minutes. TFA and anisole were removed in vacuo and the residue was dissolved in EtOAc (10 mL). The compound was extracted into a solution of NaHCO 3 (0.072 g, 0.858 mmol). The aqueous layer was loaded onto a column of the high porous polymer CHP20P (MitsubishI Chemical Corp., White Plains, NY) and elution with water to give the disalt 6k. Elution with 5% 25 EtOH/H 2 0 gave the mono salt 6d; 6 6.45 (s, 1H), 5.79 (s, 1H), 1.71 (s, 3H), 1.30 (s, 9H). The intermediate 5d was prepared as follows. 30 a. Benzhydryl-7-[(Z)-(tert-butoxycarbonyl)methylene]-3'-(desacetoxy) cephalosporinate (3d). To a solution of 2b ( 5 g, 1.31 mmol) in dry THF at -78 C was added a solution of (tert butoxycarbonylmethylene)triphenylphosphorane (4.9 g, 1.04 mmol) slowly and 30 WO 00/63213 PCT/USOO/09929 the reaction stirred for 1 hour at the same temperature under nitrogen. The reaction mixture was then quenched with a saturated solution of NH 4 Cl (75 mL) and the compound was extracted into CH 2 Cl 2 (75 mL). The organic layer was dried over Na 2
SO
4 , concentrated under reduced pressure, and purified by silica 5 gel chromatography to give 3d (3.9 g, 62%); 1H NMR, 400 MHZ, CDC1 3 , 6 7.48-7.26 (in, 10H), 6.95 (s, 1H), 6.34 (s, 1H), 5.45 (s, 1H), 3.48 (d, J = 18.1 Hz, 1H), 3.22 (d, J = 18.1 Hz, 1H), 2.12 (s, 3H), 1.52 (s, 9H). b. Benzhydryl 7-[(tert-butoxy)methylene]-3' 10 (desacetoxy)cephalosporinate Sulfone (4d). To a solution of sulfide 3d (2 g, 4.16 mmol) in CH 2 Cl 2 (25 mL) was added m-CPBA (70%) (4g, 23.2 mmol) and phosphate 6.4 buffer (25 mL) and the reaction stirred for 1 hour at room temperature. The reaction mixture was then diluted with CH 2 Cl 2 and the organic layer was washed with Na 2
SO
3 (2 x 20 mL) followed by NaHCO 3 (2 x 25 mL). 15 The product was extracted into CH 2 Cl 2 , dried over sodium sulphate, concentrated under reduced pressure, and purified by silica gel column chromatography to give compound 4d (1.5 g, 71%); 'H NMR, 400 MHZ, CDC 3 , 8 7.46-7.26 (in, 10H), 6.94 (s, 1H), 6.54 (s, 1H), 5.40 (s, 1H), 3.86 (d, J = 16.8 Hz, 1H), 3.73 (d, J = 16.8 Hz, 1H), 2.17 (s, 3H), 1.54 (s, 9H). 20 c. Benzhydryl 7-[(Z)-(tert-butoxycarbonyl)methylene]-3'-desacetoxy-2 (exomethylidene)cephalosporinate Sulfone (5d). To a solution of sulfone 4d (0.475 g, 0.92 mmol) in dry CH 3 CN (10 mL) at 0 'C was added Eschenmoser's salt (0.685 g, 2.76 mmol) and the reaction mixture stirred at this temperature for 25 3 hours. CH 3 CN was removed under reduced pressure and the residue was dissolved in CH 2 Cl 2 and washed with water. The organic layer was dried over Na 2
SO
4 and concentrated under reduced pressure to give compound 5d (0.31 g, 63.7%); 'H NMR (400 MHZ, CDCl 3 ) 6 7.43-7.26 (in, 10H), 7.0 (s, 1H), 6.7 (s, 1H), 6.59 (s, 1H), 6.13 (s, 1H), 5.65 (s, 1H), 2.17 (s, 3H), 1.53 (s, 9H). 30 Example 5: Sodium salt of Benzhydryl 7-[(Z)-(tert Butylcarboxy)methylene] 31 WO 00/63213 PCT/USOO/09929 3'-desacetoxy-2-exomethylidene-3'-[1"-methyl-1"H-tetrazol- 5" yl)thio]cephalosporinate Sulfone (6f). To a solution of compound 5f (0.22 g, 0.34 mmol) in anisole 5 (1.13 mL, 10.2 mmol) at 0 'C was added TFA (1.6 mL) and the reaction was stirred for 10 minutes. TFA and anisole were removed in vacuo. The residue was dissolved in EtOAc and the compound was extracted into an aqueous solution of NaHCO 3 (0.043 g, 0.51 mmol). The aqueous layer was loaded onto a column of the high porous polymer CHP20P (MitsubishI Chemical Corp., White 10 Plains, NY) and eluted with 5% EtOH/H 2 0 to give compound 6f; 'H NMR (400 MHZ, D 2 0) 6 6.66 (s, 1H), 6.60 (s, 1H), 6.31 (s, 1H), 6.10 (s, 1H), 4.41 (d, J= 13.7 Hz, 1H), 3.94 (s, 3H), 1.43 (s, 9H). The intermediate compound 5f was prepared as follows. 15 a. Benzhydryl (3-Chloromethyl)-7-oxocephalosporinate (2c). To a solution of benzhydryl 7-amino-3-(chloromethyl)cephalosporinate (4 g, 9.7 mmol) in EtOAc (100 mL) was added isoamylnitrite (1.55 mL, 11.6 mmol) and a catalytic amount of TFA (201) and the resulting solution was allowed to stir for 25 minutes. Volatiles were removed under reduced pressure to give a yellow 20 solid which was identified as 7-diazo compound. The yellow solid was then dissolved in benzene (25 mL) and propylene oxide (50 mL, 1164 mmol) was added followed by rhodium octanoate (50 mg). The reaction mixture was stirred for 10 minutes and then concentrated under reduced to obtain ketone 2c as a yellow solid; 'H NMR (CDC13, 400 MHZ), 8 7.45-7.35 (m, 10H), 7.0 (s, 1H), 25 5.3 (s, 1H), 4.34 (d, J = 13.8 Hz, 1H), 4.37 (d, J = 13.8 Hz, 1H), 3.69 (d, J = 18 Hz, 1H), 3.56 (d, J = 18 Hz, 1H). b. Benzhydryl 7-[(Z)-(tert-butoxycarbonyl)methylene]-3'-chloro 3'-(desacetoxy)cephalosporinate (3e). To a solution of ketone 2c (3.87 g, 9.41 30 mmol) in dry THF at -78'C was added a solution of 1-tert butoxycarbonylmethylene-triphenylphosphorane (2.83 g, 7.5 mmol) slowly and the reaction stirred for 1 hour at the same temperature under nitrogen. The reaction mixture was quenched with a saturated solution of NH 4 C1 (75 mL) and 32 WO 00/63213 PCT/USOO/09929 the compound was extracted into CH 2 C1 2 (75 mL). The organic layer was dried over Na 2
SO
4 , concentrated under reduced pressure, and purified on silica gel chromatography to give compound 3e (2.94 g, 61%); 'H NMR (400 MHZ, CDCl 3 ) 8 7.44-7.26 (m, 10 H), 6.98 (s, 1H), 6.6 (s, 1H), 5.5(s, 1H), 4.59 (d, J= 5 12.4 Hz, 1H), 4.38 (d, J= 12.4 Hz, 1H), 4.19 (d, J = 17.54 Hz, 1H), 3.8 (d, J= 17.54 Hz, 1H), 1.5 (s, 9H). c. Benzhydryl 7-[(Z)-(tert-butoxycarbonyl)methylenel-3'-chloro-3' (desacetoxy)cephalosporinate (4e). To a solution of 3e (0.53 g, 1.04 mmol) in 10 CH 2 Cl 2 (10 mL) was added m-CPBA (70%) (0.56g, 2.27 mmol) and phosphate 6.4 buffer (10 mL) and the reaction stirred for 1 hour. The reaction mixture was diluted with CH 2 Cl 2 and the organic layer was washed with Na 2
SO
3 (2 x 20 mL) followed by NaHCO 3 (2 x 25 mL) and the product was extracted into CH 2 Cl 2 (20 mL), dried over sodium sulphate, concentrated under reduced pressure and 15 purified by silica gel column chromatography to give 0.39 g (71%) of 4e. 'H NMR (400 MHZ, CDC1 3 ) 8 7.44-7.25 (m, 10H), 6.98 (s, 1H), 6.59 (s, 1H), 5.53 (s, 1H), 4.58 (d, J = 12.4 Hz, 1H), 4.37 (d, J = 12.4 Hz, 1H), 4.14 (d, J = 17.5 Hz, 1H), 3.82 (d, J = 17.5 Hz, 1H), 1.5 (s, 9 H). 20 d. Benzhydryl 7-[(Z)-(tert-Butylcarboxy)methylene]-3'-desacetoxy 3'-[l" -methyl-i "H-tetrazol-5 "-yl)thiol cephalosporinate Sulfone (4f). To a solution of 5-mercapto-1-methyltetrazole (0.65 g, 1.02 mmol) in acetone (9 mL) and H 2 0 (3 mL) was added NaHCO 3 (0.095 g, 1.13 mmol) followed by compound 4e. The reaction was stirred for 3 hours. The reaction mixture was 25 then washed with water (10 mL) and the compound was extracted with CH 2 C1 2 . The organic layer was dried over Na 2
SO
4 and concentrated under reduced pressure to give 0.57g (89%) of compound 4f; 'H NMR (400 MHZ, CDC1 3 ) 6 7.47-7.26 (m, 1OH), 6.94 (s, 1H), 6.56 (s, 1H), 4.66 (d, J = 13.98 Hz, 1H), 4.44 (d, J = 13.98 Hz, 1H), 4.11 (d, J = 17.5 Hz, 1H), 4.01 (d, J = 17.59 Hz, 1H), 3.87 30 (s, 3H), 1.51 (s, 9H). e. Benzhydryl 7-[(Z)-(tert-Butylcarboxy)methylenel-3'-desacetoxy 33 WO 00/63213 PCT/USOO/09929 2-exomethylidene-3'-[1"-methyl-1"H-tetrazol-5"-yl)thio]cephalosporinate Sulfone (5f). To a solution of sulfone 4f (0.25 g, 0.40 mmol) in dry CH 3 CN (10 mL) at 0 0 C was added Eschenmoser's salt (0.223 g, 1.2 mmol) and the reaction was stirred at this temperature for 2 hours. CH 3 CN was then removed under 5 reduced pressure. The residue was dissolved in CH 2 Cl 2 (25 mL) and the solution washed with water (2 x 15mL). The organic layer was dried over Na 2
SO
4 and concentrated to produce compound 5f (0.22 g, 88%); 'H NMR (400 MHZ, CDCl 3 ) 6 7.43-7.26 (m, 10H), 6.99 (s, 1H), 6.80 (s, 1H), 6.67 (d, J = 14 Hz, 2H), 5.69 (s, 1H), 4.72 (d, J = 13.84 Hz, 1H), 4.34 (d, J = 13.84 Hz, 1H), 4.11 (d, J= 10 17.59 Hz, 1H), 3.83 (s, 3H), 1.51(s, 9H). Example 6: Sodium [2-[(bisthiomethyl)exomethylene]-7-[(Z)-(2" pyridinyl)methylenel-3'- desacetoxycephalosporinate (6g). 15 To a solution of compound 5g (0.2 g, 0.35 mmol) in anisole (1.16 mL) at 0 'C was added TFA (2.75 mL, 42 mmol) and the reaction stirred for 10 minutes. TFA and anisole were removed in vacuo. The residue was dissolved in EtOAc and the compound was extracted into an aqueous solution of NaHCO 3 [0.045 g / 1OmL H 2 0, 0.53 mmol]. The aqueous layer was loaded onto a column 20 of the high porous polymer CHP20P (MitsubishI Chemical Corp., White Plains, NY) and the compound was eluted in 5-10% EtOH/H 2 0 to give compound 6g; NMR (400 MHZ, D 2 0) 6 8.51 (d, J = 4 Hz, 1H), 7.80 (1H), 7.61 (d, J = 7.8 Hz, 1H), 7.37 (m, 2H), 6.12 (s, 1H), 2.45 (s, 3H), 2.32 (s, 3H), 2.04 (s, 3H). 25 The intermediate compound 5g was prepared as follows. a. Benzhydryl 3'-Desacetoxy-2-[exo(bisthiomethyl)methylidene]-7 [(Z)(2"-pyridinyl)methylenelcephalosporinate Sulfone (5g). To a solution of sulfone 4c (0.2 g, 0.41 mmol) in dry DMF (3 mL) at 0 'C was added NaH (60%, 30 0.032 g, 1.36 mmol) followed by CS 2 (0.197 mL, 3.28 mmol) and CH 3 I (0.077 mL, 1.22 mmol) and the reaction was stirred for 30 minutes. To the bright yellow reaction mixture was added crushed ice and the compound was extracted into toluene (15 mL). The toluene layer was dried, concentrated under pressure 34 WO 00/63213 PCT/USOO/09929 and purified on a silica gel column chromatography to produce compound 5g (0.2 g, 87%); 'H NMR (400 MHZ, CDCl 3 ) 8 8.71 (d, 1H), 7.72 (1H), 7.51 (2H), 7.39-7.23 (in, 11H), 6.95 (s, 1H), 5.68 (s, 1H), 4.15 (d, J = 7.16 Hz, 1H), 4.11 (d, J = 7.16Hz, 1H), 2.52 (s, 3H), 2.49 (s, 3H), 2.3 8 (s, 3H). 5 Example 7: Disodium Salt of 7-[(Z)-(Carboxy)methylene]- 2 (exomethylidene)-cephalosporinate Sulfone (6h) To a solution of ester 5b (0.68 g, 1.16 mmol) in anisole (3.79 mL, 10 34.9 mmol) at 0 'C was added TFA (10.8 mL, 139 mmol) and the reaction mixture stirred for 10 minutes. TFA and anisole were removed in vacuo and the residue was dissolved in EtOAc and extracted into a solution of NaHCO 3 (0.146 g/10 mL H 2 0). The aqueous layer was then loaded onto a column of the high porous polymer CHP20P (MitsubishI Chemical Corp., White Plains, NY) and 15 compound 6h was eluted with water; 'H NMR (400 MHZ, D 2 0) 6h 8 6.71 (s, 1H), 6.51 (s, 1H). 6.35 (s, 2H), 5.1 1 (d, J= 11 Hz), 4.8 (d, J= 11 Hz, 1H), 2.04 (s, 3H), 1.46 (s, 9H). Example 8: Disodium Salt 7-[(Z)(carboxy)methylene]-3'-desacetoxy-2 20 (exo- methylidene)cephalosporinate Sulfone (6i). To a solution of ester 5d (0.3 g, 0.572 mmol) in anisole (1.86 mL, 17.2 mmol) at 0 'C was added TFA (2.65 mL, 34.3 mmol) and the reaction stirred for 10 minutes. TFA and anisole were removed in vacuo and the residue 25 was dissolved in EtOAc (10 mL). The compound was extracted into a solution of NaHCO 3 (0.072 g, 0.858 mmol). The aqueous layer was loaded onto a column of the high porous polymer CHP20P (MitsubishI Chemical Corp., White Plains, NY) and elution with water gave the disalt 6i; 'H NMR (400 MHZ, D 2 0) 8 6.69 (s, 1H), 6.49 (s, 1H), 6.12 (s, 1H), 5.88 (s, 1H), 1.9 (s, 3H). 'H NMR (400 30 MHZ, D 2 0) 6d, 6 6.45 (s, 1H), 5.79 (s, 1H), 1.71 (s, 3H), 1.30 (s, 9H). Examples 9-19 35 WO 00/63213 PCT/USOO/09929 The following compounds were prepared as illustrated in Figures 3 and 4: Benzhydryl 3-(acetoxymethyl)-7Z-[(2'-pyridyl)methylidenel-3 cephem-4-carboxylate (7) was prepared from 2 using a procedure similar to that 5 described by J. D. Buynak et. al. J. Med. Chem. 38, 1022-1034, 1995. Benzhydryl 3-(acetoxymethyl)-7Z-[(2'-pyridyl)methylidene]-2 cephem-4-carboxylate (8). A solution of 7 (7.0 g, 13.6 mmol) and Et 3 N (1.58 g, 15.6 mmol in CHC1 3 was heated at reflux for 4 hours under argon. The reaction mixture was concentrated in vacuo and the residue was purified by flash 10 chromatography on silica (eluent: 5 to 15% EtOAc in hexane) to provide 3.88 g (55%) 8 and 1.3 g (18.5%) 7; 'H NMR (CDCl 3 ): 6 1.94 (s, 3H), 4.65, 4.56 (ABq, J= 25.5 Hz, 2H), 5.26 (s, 1H), 5.89 (s, 1H), 6.48 (s, 1H), 6.91 (s, 1H), 6.94 (s, 1H), 7.36-7.23 (in, 12H), 7.70 (t, J = 2.2 Hz, 1H), 8.60 (d, J = 4.2 Hz, 1H). Benzhydryl 3-(hydroxymethyl)-7Z-[(2'-pyridyl)methylidene]-2 15 cephem-4-carboxylate (9). To a solution of 8 (1.1 g, 2.14 mmol) in CH 2 C1 2 (5 mL), was added H 2 0 (0.1 mL) and then a second solution ofp-toluenesulfonic acid (0.46 g, 2.46 mmol) in CH 3 0H (10 mL). The reaction was stirred for 24 to 30 hours. The solvent was removed in vacuo. The residue was dissolved in CH 2 C12 (20 mL), washed with saturated aqueous NaHCO 3 , water and brine, and dried over Na 2
SO
4 . 20 The solvent was removed in vacuo and the product purified by flash chromatography on silica (eluent: 25% EtOAc in hexane) to provide 525 mg (51%) 9; 'H NMR (CDCl 3 ): 6 4.14, 4.09 (ABq, J = 16.2 Hz, 2H), 5.32 (s, 1H), 5.70 (s, 1H), 5.90 (s, 1H), 6.92 (s, 1H), 6.94 (s, 1H), 7.35-7.21 (in, 12H), 7.69 (t, J = 1.8 Hz, 1H), 8.60 (d, J= 4.5 Hz, 1H). 25 Benzhydryl 3-formyl-7Z-[(2'-pyridyl)methylidene]-2-cephem-4 carboxylate (10). Celite (2 g) was added to a solution of 9 (3.2 g, 6.79 mmol) in anhydrous CH 2 C1 2 at 0 'C. Pyridinium dichromate (2.93 g, 7.81 mmol) was then added in three equal portions over a 15 minute period. The reaction was allowed to 30 stir at 0 'C for 2 hours. The reaction mixture was then filtered and the filtrate passed quickly through a small bed of silica gel and concentrated in vacuo to provide 2.6 g (81%) of 10; 'H NMR (CDCl 3 ): 6 5.72 (s, 1H), 5.88 (s, 1H), 6.84 (s, 1H), 6.98 36 WO 00/63213 PCT/USOO/09929 (s, 1H), 7.37-7.25 (in, 12H), 7.58 (s, 1H), 7.71 (t, J = 2.2 Hz, 1H), 8.60 (d, J = 3.9 Hz, 1H), 9.30 (s, 1H). General Procedure for the preparation of Alkenes 11a, lib, lid, and lie. A solution of aldehyde 10 (0.5 mmol) and the requisite ylide (5.0 mmol) 5 was stirred in anhydrous THF (10 mL) at room temperature for approximately 24 hours. The solvent was removed in vacuo and the residue was purified by flash chromatography on silica using 5 to 20% EtOAc in hexane (in the case of compound 11d, 2% MeOH in CH 2 Cl 2 was required). Benzhydryl 3-12'E-(cyanoethenyl)]-7Z-[(2"-pyridyl)methylidenel 10 2-cephem-4-carboxylate (11a). Using the general procedure described above, the title compound was prepared; yield: 82%; 'H NMR (CDCl 3 ): 8 5.30-5.34 (in, 2H), 5.98 (s, 1H), 6.90-6.84 (in, 2H), 6.98 (s, 1H), 7.40-7.28 (in, 13H), 7.73 (t, J = 1.6 Hz, 1H), 8.62 (d, J = 3.78 Hz, 1H). Benzhydryl 3-[2'E-(methoxycarbonylethenyl)]-7Z-[(2" 15 pyridyl)methylidene]-2-cephem-4-carboxylate (11b). Using the general procedure described above, the title compound was prepared; yield: 96%; 1 H NMR (CDCl 3 ): 6 3.67 (s, 3H), 5.38 (s, 1H), 5.85 (d, J = 18.0 Hz, 1H), 5.91 (s, 1H), 6.78 (s, 1H), 6.82 (s, 1H), 6.90 (s, 1H), 7.10-7.28 (in, 13 H), 7.60-7.64 (in, 1H), 8.55 (d, J= 4.0 Hz, 1H). 20 Benzhydryl 3-[2'E-(2"-pyridyl)ethenyl]-7Z-[(2"' pyridyl)methylidenel-2-cephem-4-carboxylate (11c). To a slurry of triphenyl(2 pyridylmethyl)phosphonium chloride (0.39 g, 0.75 mmol) in anhydrous THF (20 mL) was added NaNH 2 (29 mg, 0.75 mmol) under argon and the reaction allowed to stir at room temperature for 2 hours. The reaction mixture allowed to settle for an 25 additional 2 hours. The clear upper layer was carefully cannulated under argon into another flask containing a solution of the aldehyde 10 (235 mg, 0.5 mmol) in anhydrous CH 2 C1 2 (10 mL) at -78 'C. The reaction was stirred for 1 hour at -78 'C, and poured into a separatory funnel containing sat. aq. NH 4 Cl. The organic layer was collected, dried on Na 2
SO
4 , and concentrated in vacuo. The residue was 30 purified by flash chromatography on silica gel using 10 to 20% EtOAc in hexane to provide 0.21 g (78%) 11c; 'H NMR (CDCl 3 ): 6 5.29 (s, 1H), 5.62 (s, 1H), 5.99 (s, 1H), 6.64 (d, J = 17.4 Hz, 1H), 6.66 (s, 1H), 6.92 (s, 1H), 6.95 (s, 1H), 7.21-7.33 (in, 37 WO 00/63213 PCTIUSO0/09929 14H), 7.62 - 7.63 (m, 1H), 7.69 (t, J = 2.8 Hz, 1H), 8.54 (d, J = 4.52 Hz, 1H), 8.60 (d, J = 3.84 Hz, 1H). Benzhydryl 3-[prop-l'E-ene-3'-amide)]-7Z-[(2" pyridyl)methylidene]-2-cephem-4-carboxylate (11d). Using a procedure similar 5 to that described by S. Trippet, and D. M. Walker, J. Chem. Soc. 3874, 1959, the requisite ylide (carbamoylmethylenetriphenyl-phosphorane) was obtained as follows: A solution of carbamoylmethyltriphenyl-phosphonium chloride (5 g, 14.0 mmol), (itself obtained from chloroacetamide and triphenylphosphine in refluxing nitromethane) in H 2 0 (75 mL) was cooled to 0 'C and a cold (0 - 5 'C) solution of 10 NaOH (0.56 g in 5 mL H 2 0) was added in one portion. The resultant mixture was immediately filtered and washed with cold water (75 mL). The collected precipitate was dried under high vacuum to provide carbamoylmethylenetriphenylphosphorane. This ylide was reacted with aldehyde 10 according to the general procedure above to give the title compound; yield: 78%; 1H NMR (CDCl 3 ): 8 5.41 (s, 1H), 5.70 (d, J= 15 15.5 Hz, 1H), 5.95 (s, 1H), 6.84 (s, 1H), 6.87 (s, 1H), 6.96 (s, 1H), 7.23-7.36 (m, 13H), 7.69-7.72 (m, 2H), 8.60 (d, J = 4.12 Hz, 1H). Benzhydryl 3-[2'E-(tert-butoxycarbonyl)ethenyll-7Z-[(2" pyridyl)methylidene]-3-cephem-4-carboxylate (11e). Using the general procedure described above, the title compound was prepared; 'H NMR (CDCl 3 ): 5 1.48 (s, 9H), 20 5.44 (s, 1H), 5.92 (d, J = 15.8 Hz, 1H), 5.96 (s, 1H), 6.78 (s, 1H), 6.87 (s, 1H), 6.94 (s, 1H), 7.13 (d, J = 15.8 Hz, 1H), 7.23-7.34 (m, 12H), 7.70 (t, J = 7.7 Hz, 1H), 8.60 (d, J= 4.12 Hz, 1H). Benzhydryl 3-[2'Z-chloro-2'-(methoxycarbonyl)ethenyl-7Z-[(2" pyridyl)methylidene]-2-cephem-4-carboxylate (I1f). A solution of methyl 25 (triphenylphosphoranylidene) acetate (0.267 g, 0.79 mmol) in anhydrous THF was chilled to -20 'C and N-chlorosuccinimide (0.1 g, 0.79 mmol) and NaHCO 3 (0.1 g, 7.5 mmol) was added. After stirring for 30 minutes at -20 0 C, aldehyde 10 (75 mg, 0.15 mmol) was added. The reaction was allowed to come to room temperature and was stirred for 36 hours. The solvent was removed in vacuo and the residue was 30 purified by flash chromatography on silica to provide 73 mg (82%) 11f; 'H NMR (CDCl 3 ): 8 3.72 (s, 3H), 5.44 (s, 1H), 5.96 (s, 1H), 6.84 (s, 1H), 6.87 (s, 1H), 6.95 (s, 1H), 7.27-7.69 (m, 13H), 7.69 (t, J = 7.34 Hz, 1H), 8.60 (d, J = 3.58, 1H). 38 WO 00/63213 PCT/USOO/09929 Benzhydryl 3-[2'E-nitroethenyl]-7Z-[(2 "-pyridyl)methylidene]-2 cephem-4-carboxylate (11h). A solution of aldehyde 10 (50 mg, 0.107 mmol), AcOH (63 mg, 1.07 mmol), and NH40Ac (41 mg, 0.533 mmol) in CH 3
NO
2 (2 mL) was heated at 50 'C for 2 hours. The reaction was monitored by tic, and if it was 5 not complete, an additional quantity of NH 4 0Ac (20 mg, 0.26 mmol) was added and stirring was continued for an additional 1 hour. Volatiles were removed in vacuo and the residue was redissolved in CH 2 Cl 2 (20 mL). The resultant solution was washed with water, brine, and dried over Na 2
SO
4 . Concentration in vacuo and purification by flash chromatography on silica gel provided 48 mg (92%) 11h as a 10 yellow solid; 'H NMR (CDCl 3 ): 8 5.33 (s, 1H), 6.02 (s, 1H), 6.91 (s, 1H), 7.00 (s, 1H), 7.13 (s, 1H), 7.23 (d, J = 13.8 Hz, 1H), 7.27-7.36 (m, 12H), 7.50 (d, J = 13.8 Hz, 1H), 7.73 (t, J = 7.24 Hz, 1H), 8.62 (d, J = 4.22 Hz, 1H). Benzhydryl 3-(E-oximinomethyl)-7Z-[(2'-pyridyl)methylidene]-2 cephem-4-carboxylate (14). A solution of aldehyde 10 (0.1 g, 0.21 mmol) and 15 hydroxylamine hydrochloride (0.03 g, 0.42 mmol) in anhydrous isopropanol (4 mL) was heated at 80 'C for 3 hours. The solvent was then removed in vacuo and the residue dissolved in CH 2 C1 2 (20 mL). This solution was washed with 10% NaHC0 3 , water, and brine and dried over Na 2
SO
4 . Removal of the volatiles provided the oxime 14 (92 mg, 90%); 'H NMR (CDCl 3 ): 8 5.61 (s, 1H), 5.78 (s, 1H), 6.64 (s, 1H), 20 6.88 (s, 1H), 6.95 (s, 1H), 7.22-7.38 (m, 12H), 7.65-7.68 (m, 2H), 8.60 (d, J = 4.38 Hz, 1H). Benzhydryl 3-cyano-7Z-[(2'-pyridyl)methylidene]-2-cephem-4 carboxylate (17). To a solution of oxime 14 (0.1 g, 0.2 mmol) in anhydrous CHCl 3 (5 mL) was added SOCl 2 (25 mg, 0.2 mmol) by syringe and the reaction mixture was 25 heated to reflux for 30 minutes. The solution was cooled, washed with 5% aq NaHCO 3 , water, and brine, and dried over Na2SO 4 . Purification by flash chromatography on silica gel provided the nitrile 17 (78 mg, 82%); 'H NMR (CDCl 3 ): 8 5.30 (s, 1H), 5.48 (s, 1H), 5.89 (s, 1H), 6.92 (s, 1H), 6.99 (s, 1H), 7.21 7.47 (m, 12H), 7.71 (t, J = 7.41 Hz, 1H), 8.57 (d, J = 4.4 Hz, 1H). 30 General Procedure for Formation of Sulfones 12a, 12b, 12c, 12d, 12e, 12f, 12h, 15, and 18. To a biphasic mixture of CH 2 Cl 2 (20 mL) and buffer (pH = 6.4, phosphate buffer, Aldrich Chemical Co., 10 mL), was added the requisite sulfide prepared above, (0.2 mmol) and MCPBA (1.0 mmol) at room temperature. 39 WO 00/63213 PCT/USOO/09929 The reaction was stirred for 30 minutes. The organic layer was separated and washed with saturated aqueous NaHSO 3 , saturated aqueous NaHCO 3 , water, and brine. Removal of the solvent in vacuo provided the sulfone 12 (quantitative yield). Benzhydryl 3-[2'E-(cyanoethenyl)]-1,1-dioxo-7Z-[(2" 5 pyridyl)methylidene]-3-cephem-4-carboxylate (12a). Using the general procedure described above, the title compound was prepared; 'H NMR (CDCl 3 ): 6 3.81 (d, J = 17 Hz, 1H), 4.04 (d, J = 17 Hz, 1H), 5.34 (d, J = 16.5 Hz, 1H), 6.05 (s, 1H), 7.12 (s, 1H), 7.35-7.55 (m, 14H), 7.78 (s, 1H), 8.72 (s, 1H). Benzhydryl 1,1-dioxo-3-[2'E-(methoxycarbonylethenyl)]-7Z-[(2" 10 pyridyl)methylidene]-3-cephem-4-carboxylate (12b). Using the general procedure described above, the title compound was prepared; 'H NMR (CDCl 3 ): 5 3.68 (s, 3H), 3.78 (d, J = 17.2 Hz, 1H), 4.02 (d, J = 17.2 Hz, 1H), 5.86-5.92 (m, 2H), 7.01 (s, 1H), 7.25-7.36 (m, 12H), 7.44 (d, 1H, J = 4.22 H, 7.66-7.70 (m, 1H), 7.87 (d, J = 15.9 Hz, 1H), 8.63 (d, J = 4.27 Hz, 1H). 15 Benzhydryl 1,1-dioxo-3-{2'E-[2" -(pyridin-N-oxide)ethenyl]}-7Z [(2"'-pyridyl)methylidenel-3-cephem-4-carboxylate (12c). Using the general procedure described above, the title compound was prepared; 'H NMR (CDCl 3 ): 6 4.12 (d, J = 17.1 Hz, 1H), 4.35 (d, J = 17.1 Hz, 1H), 5.27 (s, 1H), 7.03 (s, 1H), 7.26 7.69 (m, 18H), 8.17 (s, 1H), 8.66 (s, 1H). 20 Benzhydryl 1,1-dioxo-3-[prop-1'E-ene-3'-amide)]-7Z-[(2 " pyridyl)methylidene]-3-cephem-4-carboxylate (12d). Using the general procedure described above, the title compound was prepared; 'H NMR (CDCl 3 ): 6 3.87 (d, J = 17.1 Hz, 1H), 4.07 (d, J = 17.1 Hz, 1H), 5.44 (brs, 2H), 5.94-5.98 (m, 2H), 7.05 (s, 1H), 7.25-7.68 (m, 10H), 7.51-7.56 (m, 2H), 7.64-7.74 (m, 2H), 7.80 25 (d, J = 15.8 Hz, 1H), 8.68 (d, J = 4.32 Hz, 1H). Benzhydryl 3-[2'E-(tert-butoxycarbonyl)ethenyl]-1,1-dioxo-7Z [(2"-pyridyl)methylidene]-3-cephem-4-carboxylate (12e). Using the general procedure described above, the title compound was prepared; 'H NMR (CDCl 3 ): 6 1.46 (s, 9H), 3.78 (d, ABq, J = 20.5 Hz, 1H), 4.06 (d, ABq, J = 20.5 Hz, 1H), 5.88 30 (d, J = 18.1 Hz, 1H), 5.95 (s, 1H), 6.04 (s, 1H), 6.22 (d, J = 18.1 Hz, 1H), 6.88 (s, 1H), 7.04 (s, 1H), 7.24-7.52 (m, 12H), 7.73-7.75 (m, 1H), 8.68 (s, 1H). Benzhydryl 1,1-dioxo-3-[2'Z-chloro-2' (methoxycarbonyl)ethenyll-7Z-[(2"-pyridyl)methylidenel-3-cephem-4 40 WO 00/63213 PCT/USOO/09929 carboxylate (12f). Using the general procedure described above, the title compound was prepared; 'H NMR (CDCl 3 ): 8 3.73 (s, 3H), 3.87 (d, J = 17.2 Hz, 1H), 4.02 (d, J = 17.2 Hz, 1H), 5.91 (s, 1H), 5.95 (s, 1H), 5.98 (s, 1H), 7.06 (s, 1H), 7.29-7.39 (m, 12H), 7.89-7.93 (m, 1H), 8.66 (d, J = 4.24 Hz, 1H). 5 Benzhydryl 1,1-dioxo-3-[2'E-nitroethenyl]-7Z-1(2 " pyridyl)methylidene]-3-cephem-4-carboxylate (12h). Using the general procedure described above, the title compound was prepared; 'H NMR (CDCl 3 ): 6 3.94 (d, J = 18.1 Hz, 1H), 4.12 (d, J = 18.1 Hz, 1H), 5.98 (s, 1H), 6.96 (s, 1H), 7.04 (d, J = 14.6 Hz, 1H), 7.12 (s, 1H), 7.26-7.38 (m, 12H), 7.54 (d, J = 14.6 Hz, 1H), 10 7.74 (t, J= 7.86 Hz, 1H), 8.61 (d, J = 4.22 Hz, 1H). Benzhydryl 3-[2'E-(tert-butoxycarbonyl)ethenyl]-1,1-dioxo-2 methylidene-7Z-[(2"-pyridyl)methylidene]-3-cephem-4-carboxylate (20). To a solution of sulfone 12e (0.1 mmol) in anh CH 3 CN (10 mL), Eschenmoser's salt (0.4 mmol) was added at room temperature. The reaction was stirred under argon for 3 15 hours. CH 3 CN was removed under reduced pressure and the residue dissolved in
CH
2 C1 2 (15 mL). The CH 2 Cl 2 layer was then washed with water and brine, and dried over Na 2
SO
4 . Purification by flash chromatography on silica gel using 5% EtOAc/CH 2 Cl 2 provided 20 (90% yield); 'H NMR (CDCl 3 ): 6 1.38 (s, 9H), 5.95 (d, J = 16.0 Hz, 1H), 6.01 (s, 1H), 6.14 (s, 1H), 6.70 (s, 1H), 6.94 (s, 1H). 7.25-7.40 (m, 20 14H), 7.82 (t, J = 6.68 Hz, 1H), 8.61 (d, J = 3.84 Hz, 1H). Benzhydryl 1,1-dioxo-3-(E-oximinomethyl)-7Z-[(2' pyridyl)methylidene]-3-cephem-4-carboxylate (15). Using the general procedure described above, the title compound was prepared; 'H NMR (CDCl 3 ): 6 4.08 (d, J= 17.4 Hz, 1H), 4.30 (d, J = 17.4 Hz, 1H), 5.88 (s, 1H), 6.99 (s, 1H), 7.12 - 7.24 (m, 25 13H), 7.42 - 7.52 (m, 2H), 8.62 (d, J = 3.9 Hz, 1H). Benzhydryl 1,1-dioxo-3-cyano-7Z-[(2'-pyridyl)methylidene]-3 cephem-4-carboxylate (18). Using the general procedure described above, the title compound was prepared; 'H NMR (CDCl 3 ): 6 3.82 (d, J = 18.2 Hz, 1H), 4.12 (d, J = 18.2 Hz, 1H), 5.47 (s, 1H), 6.02 (s, 1H), 7.04 (s, 1H), 7.21-7.46 (m, 12H), 7.72 (t, J 30 = 8.2 Hz, 1H), 8.66 (d, J = 4.52 Hz, 1H). General Procedure for Conversion of Benzhydryl Esters (12a, 12b, 12c, 12d, 12e, 12f, 12h, 15, 18 and 20) to the Corresponding Sodium Carboxylates (13a, 13b, 13c, 13d, 13e, 13f, 13g, 13h, 16, 19, and 21). A solution 41 WO 00/63213 PCT/USOO/09929 of the benzhydryl ester (0.1 mmol) in anisole (3.0 mmol) was cooled in an ice-salt bath and TFA (12.0 mmol) was slowly added via syringe under argon. After 20 minutes, the volatiles were removed in vacuo and the residue was dissolved in EtOAc (5 mL). The EtOAc layer was extracted with aqueous NaHCO 3 (2 x 0.15 5 mmol in 4 mL H 2 0). The combined NaHCO 3 layers were directly loaded on a column (high porous polymer, MCI gel, CHP20P, Mitsubishi Chemical Corp., White Plains, NY, approx. 75 to 150 mL of resin) and the product eluted with 5% EtOH in deionized (millipore) water. Yields were between 60 to 80%. 10 Example 9: Sodium 3-[2'E-(cyanoethenyl)]-1,1-dioxo-7Z-[(2" pyridyl)methylidene]-3-cephem-4-carboxylate (13a); 'H NMR (D 2 0): 6 5.55 (d, J = 16.4 Hz, 1H), 6.40 (s, 1H), (7.46, t, J = 5.12 Hz, 1H), 7.50 (d, J = 16.4 Hz, 1H), 7.59 (s, 1H), 7.68 (d, J = 7.76 Hz, 1H), 7.89 (t, J= 7.62 Hz, 1H), 8.62 (d, J = 4.54 Hz, 1H). 15 Example 10: Sodium 1,1-dioxo-3-[2'E-(methoxycarbonylethenyl)]-7Z-[(2" pyridyl)methylidene]-3-cephem-4-carboxylate (13b); 'H NMR (D 2 0): 6 3.72 (s, 3H), 5.70 (d, J = 22.0 Hz, 1H), 7.46-7.43 (m, 2H), 7.53 (s, 1H), 7.68-7.62 (m, 2H), 7.88 (t, J = 6.70 Hz, 1H), 8.60 (d, J = 4.1 Hz, 1H). 20 Example 11: Sodium 1,1-dioxo-3-{2'E-[2"-(pyridin-N-oxide)ethenyl]}-7Z [(2"'-pyridyl)methylidene]-3-cephem-4-carboxylate (13c); 'H NMR (D 2 0): 6 6.04 (s, 1H), 7.03 (d, J = 16.5 Hz, 1H), 7.39 (t, J = 6.9 Hz, 1H), 7.45 (t, J = 4.96 Hz, 1H), 7.52-7.62 (m, 4H), 7.80 (d, J = 8.1 Hz, 1H), 7.88 (t, J = 7.75 Hz, 1H), 8.23 (d, J 25 = 6.46 Hz, 1H), 8.62 (d, J = 4.38 Hz). Example 12: Sodium 1,1-dioxo-3-[prop-1'E-ene-3'-amide)]-7Z-[(2" pyridyl)methylidene]-3-cephem-4-carboxylate (13d); 'H NMR (D 2 0): 6 6.04 (d, J = 15.6 Hz, 1H), 6.38 (s, 1H), 7.47 - 7.57 (m, 3H), 7.68 (d, J = 7.6 Hz, 1H), 7.89 (brs, 30 1H), 8.61 (s, 1H). Example 13: Sodium 1,1-Dioxo-3-[2'E-(t-butoxycarbonylethenyl)]-7Z-[(2" pyridyl)methylidene]-3-cephem-4-carboxylate (13e); 'H NMR (D 2 0): 6 1.45 (s, 42 WO 00/63213 PCT/USOO/09929 9H), 5.88 (d, J = 15.8 Hz, 1H), 6.39 (s, 1H), 7.46 (t, J = 5.09 Hz, 1H), 7.55-7.61 (m, 2H), 7.69 (d, J= 11.8 Hz, 1H), 7.90 (t, J= 8.11 Hz, 1 H), 8.62 (d, J= 4.73 Hz, 1H). Example 14: Sodium 1,1-dioxo-3-[2'Z-chloro-2'-(methoxycarbonyl)ethenyl] 5 7Z-[(2"-pyridyl)methylidenel-3-cephem-4-carboxylate (13f); 'H NMR (D 2 0): S 3.81 (s, 3H), 6.0 (d, J = 15.8 Hz, 1H), 6.46 (s, 1H), 7.53 (t, J - 7.52 Hz, 1H), 7.64 (s, 1H), 7.74 - 7.71 (m, 1H), 7.95 (t, J = 7.77 Hz, 1H), 8.68 (d, J = 4.52 Hz, 1H). Example 15: Disodium 3-[2'E-carboxyethenyll-1,1-dioxo-7Z-[(2" 10 pyridyl)methylidenel-3-cephem-4-carboxylate (13g); Hydrolysis of compound 12e under the above general conditions gave a mixture of compound 13e and the title compound 13g, which was separated by chromatography to give the title compound; 'H NMR (D 2 0): 8 5.92 (d, J = 15.8 Hz, 1H), 6.36 (s, 1H), 7.34 (d, J= 15.8 Hz, 1H), 7.45-7.48 (m, 1H), 7.55 (s, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.92 (t, J= 15 7.8 Hz, 1H), 8.63 (d, J = 3.6 Hz, 1H). Example 16: Sodium 1,1-dioxo-3-[2'E-nitroethenyl]-7Z-[(2" pyridyl)methylidene]-3-cephem-4-carboxylate (13h); 'H NMR (D 2 0): 6 6.02 (s, 1H), 7.11 (s, 1H), 7.16 (d, J = 15.6 Hz, 1H), 7.20 - 7.22 (m, 2H), 7.28 (d, J = 15.6 20 Hz, 1H), 7.78 (t, J = 6.2 Hz, 1H), 8.62 (d, J = 2.88 Hz, 1H). Example 17: Sodium 1,1-dioxo-3-(E-oximinomethyl)-7Z-[(2' pyridyl)methylidene]-3-cephem-4-carboxylate (16); 'H NMR (D 2 0): 8 _6.31 (s, 1H), 7.39 (t, J = 7.84 Hz, 1H), 7.48 (d, J = 7.78 Hz, 1H), 7.71 - 7.74 (m, 2H), 8.35 (s, 25 1H), 8.36 (d, J = 6.34 Hz, 1H). Example 18: Sodium 1,1-dioxo-3-cyano-7Z-[(2'-pyridyl)methylidene]-3 cephem-4-carboxylate (19); 'H NMR (D 2 0): 5 6.40 (s, 1H), 7.49 - 7.52 (m, 1H), 7.61 (s, 1H), 7.69 - 7.74 (m, 1H), 7.93 - 7.91 (m, 1H), 8.63 (d, J = 4.6 Hz, 1H). 30 Example 19: Disodium 3-[2'E-carboxyethenyl]-1,1-dioxo-2-methylidene-7Z [(2"-pyridyl)methylidene]-3-cephem-4-carboxylate (21); 'H NMR (D 2 0): 8 5.80 43 WO 00/63213 PCT/US00/09929 (m, 2H), 6.02 (s, 1H), 6.23 (d, J = 18.4 Hz, 1H), 7.12 (d, J= 18.4 Hz, 1H), 7.21 (s, 1H), 7.26-7.31 (m, 2H), 7.79 (t, J = 7.8 Hz, 1H), 8.51 (d, J= 4.4 Hz, 1H). Example 20: The following illustrate representative pharmaceutical dosage forms, 5 containing a compound of formula I or IV ('Compound X'), for therapeutic or prophylactic use in humans. i Tablet 1 mg/tablet 'Compound X' 100.0 10 Lactose 77.5 Povidone 15.0 Croscarmellose sodium 12.0 Microcrystalline cellulose 92.5 Magnesium stearate 3-0 15 300.0 (ii) Tablet 2 mg/tablet 'Compound X' 20.0 Microcrystalline cellulose 410.0 20 Starch 50.0 Sodium starch glycolate 15.0 Magnesium stearate 5-0 500.0 25 (iii) Capsule mg/capsule 'Compound X' 10.0 Colloidal silicon dioxide 1.5 Lactose 465.5 Pregelatinized starch 120.0 30 Magnesium stearate 3-0 600.0 (iv) Injection 1 (1 mg/mL) mg/mT 'Compound X' (free acid form) 1.0 35 Dibasic sodium phosphate 12.0 Monobasic sodium phosphate 0.7 Sodium chloride 4.5 1.0 N Sodium hydroxide solution (pH adjustment to 7.0-7.5) q.s. 40 Water for injection q.s. ad 1 mL (v) Injection 2 (10 mg/mL) mg/mL 'Compound X' (free acid form) 10.0 Monobasic sodium phosphate 0.3 45 Dibasic sodium phosphate 1.1 44 WO 00/63213 PCT/US0O/09929 Polyethylene glycol 400 200.0 01 N Sodium hydroxide solution (pH adjustment to 7.0-7.5) q.s. Water for injection q.s. ad 1 mL 5 (vi) Aerosol mg/can 'Compound X' 20.0 Oleic acid 10.0 Trichloromonofluoromethane 5,000.0 10 Dichlorodifluoromethane 10,000.0 Dichlorotetrafluoroethane 5,000.0 (vii) Tablet 1 mg/tablet 'Compound X' 100.0 15 p-lactam antibiotic 100.0 Lactose 77.5 Povidone 15.0 Croscarmellose sodium 12.0 Microcrystalline cellulose 92.5 20 Magnesium stearate 32 400.0 (viii) Tablet2 mg/tablet 'Compound X' 20.0 25 p-lactam antibiotic 20.0 Microcrystalline cellulose 410.0 Starch 50.0 Sodium starch glycolate 15.0 Magnesium stearate 52) 30 520.0 (ix) Capsule mg/capsule 'Compound X' 10.0 P-lactam antibiotic 10.0 35 Colloidal silicon dioxide 1.5 Lactose 465.5 Pregelatinized starch 120.0 Magnesium stearate 3.0 610.0 40 (x) Injection 1 mg/mL 'Compound X' (free acid form) 1.0 p-lactam antibiotic 2.0 Dibasic sodium phosphate 12.0 45 Monobasic sodium phosphate 0.7 Sodium chloride 4.5 1.0 N Sodium hydroxide solution (pH adjustment to 7.0-7.5) q.s. Water for injection q.s. ad 1 mL 45 WO 00/63213 PCTIUSOO/09929 (xi) Injection 2 mg/mL 'Compound X' (free acid form) 10.0 p-lactam antibiotic 5.0 Monobasic sodium phosphate 0.3 5 Dibasic sodium phosphate 1.1 Polyethylene glycol 400 200.0 01 N Sodium hydroxide solution (pH adjustment to 7.0-7.5) q.s. Water for injection q.s. ad 1 mL 10 (xiil Aerosol mg/can 'Compound X' 20.0 P-lactam antibiotic 20.0 Oleic acid 10.0 15 Trichloromonofluoromethane 5,000.0 Dichlorodifluoromethane 10,000.0 Dichlorotetrafluoroethane 5,000.0 The above formulations may be obtained by conventional procedures 20 well known in the pharmaceutical art. "p-lactam antibiotic" can be any compound possessing antibiotic properties (e.g. amoxicillin, piperacillin, ampicillin, ceftizoxime, cefotaxime, cefuroxime, cephalexin, cefaclor, cephaloridine, or ceftazidime). Although specific quantities of "Compound X" and "p-lactam antibiotic" are shown in the above illustrative examples, it is to be understood that 25 the compounds can be present in any ratio provided the final formulation possesses the desired antibiotic properties. All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and 30 techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention. 46
Claims (51)
1. A compound of formula I: 5R2 A R6 N ~ o R 3 COOR 4 10 (') wherein: R 1 , R 2 , R 5 , and R 6 are each independently hydrogen, (CI-CIO)alkyl, (C 2 -CIO)alkenyl, (C 2 -CIO)alkynyl, (C 3 -C 8 )cycloalkyl, (CI-CIO)alkoxy, (C 1 CIO)alkanoyl, (CI-CIO)alkanoyloxy, (C 1 -CIO)alkoxycarbonyl, aryl, heterocycle, halo, 15 cyano, nitro, -COORa, -C(=O)NRbR, -OC(=O)NRbR, NRbR, or -S(O)Rd; or R, and R 2 together with the carbon to which they are attached are (C 3 -C)cycloalkyl or a heterocycle, wherein each (C 3 -C)cycloalkyl or heterocycle is optionally substituted with (CI-CIO)alkyl, hydroxy, halo, (C 1 - CIO)alkoxy, (Ci-CIO)alkanoyloxy, or (C CIO)alkoxycarbonyl; or R 5 and R 6 together with the carbon to which they are attached 20 are (C 3 -C)cycloalkyl or a heterocycle, wherein each (C 3 -C)cycloalkyl or heterocycle is optionally substituted with (C 1 -CIO)alkyl, hydroxy, halo, (C 1 CIO)alkoxy, (C 1 - CIO)alkanoyloxy, or (CI-CIO)alkoxycarbonyl; R 3 is hydrogen (CI-CIO)alkyl (C 2 -CIO)alkeny, (C 2 -CjO)alkynyl, (C 3 C 8 )cycloalkyl, (C 1 -CIO)alkoxy, (CI-CIO)alkanoyl, (C-CIO)alkanoyloxy, (C 1 25 CIO)alkoxycarbonyl, halo, cyano, nitro, aryl, heterocycle, -COORa, -C(=O)NRbR, OC(=O)NRbRNRbR, or -S(O)Rd; R 4 is hydrogen; A is thio, sulfinyl, or sulfonyl; each n is independently 0, 1, or 2; 30 each Ra is independently hydrogen, or (C 1 -CIO)alkyl; each Rb and R, is independently hydrogen, (CI-CIO)alkyl, (C 1 CIO)alkoxy, phenyl, benzyl, phenethyl, or (C 1 -CIO)alkanoyl; 47 WO 00/63213 PCT/USOO/09929 each Rd is independently (CI-CO)alkyl, (CI-CIO)alkanoyl, aryl, heterocycle, aryl(C 1 -C 6 )alkyl, heterocycle, or heterocycle(C-C 6 )alkyl; wherein any (CI-CIO)alkyl, (C 2 -CIO)alkenyl, (C 2 -CIO)alkynyl, (C 3 C 8 )cycloalkyl, (CI-CIO)alkoxy, (CI-CIO)alkanoyl, (CI-Clo)alkanoyloxy, or (C 1 5 CIO)alkoxycarbonyl of R,, R 2 , R 3 , R 5 , and R 6 is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents independently selected from halo, hydroxy, cyano, cyanato, nitro, mercapto, oxo, aryl, heterocycle, (C 2 -C 6 )alkenyl, (C 2 C 6 )alkynyl, (C-C 6 )alkoxy, (C-C 6 )alkanoyl, (C-C 6 )alkanoyloxy, aryl(Cl C)alkanoyloxy, halo(Cl-C 6 )alkanoyloxy, heterocycle(Cl-C)alkanoyloxy, aryloxy, 10 (heterocycle)oxy, -COORa, (C 3 -C 8 )cycloalkyl, -C(=0)NRbRe, -OC(=O)NRbR, NRbRe, and -S(O)Rd; and wherein any aryl is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents independently selected from halo, hydroxy, cyano, trifluoromethyl, nitro, trifluoromethoxy, (C 1 -C 6 )alkyl, (C-C)alkanoyl, (C 15 C 6 )alkanoyloxy, (C-C)alkoxycarbonyl, -COORa, -C(=0)NRbR, -OC(=O)NRbR, NRbRr, and -S(O).Rd; or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein R, is aryl, heterocycle, or -COORa. 20
3. The compound of claim 1 wherein R, is 2-pyridyl, or -COORa.
4. The compound of claim 1 wherein R 2 is hydrogen. 25
5. The compound of claim 1 wherein R 3 is hydrogen, carboxy, or CH 2 M; wherein M is hydrogen, halo, (CI-CIO)alkanoyloxy, or heterocycle.
6. The compound of claim 1 wherein R 3 is acetoxymethyl, phenylacetoxymethyl, (3,4-dihydroxyphenyl)acetoxymethyl, chloromethyl, formyl, 30 or chloroacetoxymethyl.
7. The compound of claim 1 wherein R 3 is hydrogen, methyl, acetoxymethyl, or 1-methyl-1H-tetrazol-5-ylthiomethyl. 48 WO 00/63213 PCT/US00/09929
8. The compound of claim 1 wherein R 3 is vinyl, optionally substituted at the 2- position with halo, cyano, -COORa, trifluoromethyl, formyl, (C 3 C 8 )cycloalkyl, (C 2 - CIO)alkenyl, (C 2 -CIO)alkynyl, heterocycle, or NRbR. 5
9. The compound of claim 1 wherein R 3 is vinyl, optionally substituted at the 2- position with cyano, -COORa, (C 2 -CIO)alkenyl, or heteroaryl.
10. The compound of claim 1 wherein R 3 is 2-cyanovinyl, 2 (methoxycarbonyl)- vinyl, 2-(2-pyridyl-N-oxide)vinyl, or 1,3-butadienyl. 10
11. The compound of claim 1 which is a pharmaceutically acceptable salt of an acid of formula I wherein R 4 is hydrogen.
12. The compound of claim 1 wherein R 5 and R 6 are each independently 15 hydrogen, (C 1 -CIO)alkyl, (C 2 -CIO)alkenyl, (C 2 -CIO)alkynyl, (C 3 -C 8 )cycloalkyl, (C 1 CIO)alkoxy, (CI-CIO)alkanoyl, (CI-CIO)alkanoyloxy, (CI-CIO)alkoxycarbonyl, aryl, heterocycle, halo, cyano, nitro, -COORa, -C(=O)NRbR,, -OC(=O)NRbRC, NRbR, or S(O),,Rd. 20
13. The compound of claim 1 wherein R, and R 6 together with the carbon to which they are attached are (C 3 -C 8 )cycloalkyl or a heterocycle, optionally substituted with (CI-C 1 O)alkyl, hydroxy, halo, (CI-CIO)alkoxy, (CI-CIO)alkanoyloxy, or (CI-CIO)alkoxycarbonyl. 25
14. The compound of claim 1 wherein R 5 and R 6 are each independently hydrogen, (C 1 -CIO)alkyl, (C 3 -C)cycloalkyl, halo, -COORa or -S(O)Rd; or R 5 and R 6 together with the carbon to which they are attached are a 5, 6, or 7 membered heterocycle comprising carbon and 1 or 2 N, 0, or S. 30
15. The compound of claim 1 wherein R 5 and R 6 are each individually hydrogen. 49 WO 00/63213 PCT/USOO/09929
16. The compound of claim 1 wherein R 5 and R 6 are each individually methylthio.
17. The compound of claim 1 wherein A is sulfonyl. 5
18. The compound of claim 1 wherein A is sulfonyl; R, is 2-pyridyl, carboxy or tert-butoxy carbonyl; R 2 is hydrogen; R 3 is hydrogen, methyl, acetoxymethyl or 1-methyl-1H-tetrazol-5-ylthiomethyl; and R 5 and R 6 are the same and are each hydrogen or thiomethyl. 10
19. A pharmaceutical composition comprising a compound of any one of claims 1-18; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. 15
20. The composition of claim 19 further comprising a p-lactam antibiotic.
21. The composition of claim 20 wherein the antibiotic is amoxicillin, piperacillin, ampicillin, ceftizoxime, cefotaxime, cefuroxime, cephalexin, cefaclor, cephaloridine, or ceftazidime. 20
22. A method comprising inhibiting a p-lactamase by contacting said p lactamase with an effective amount of a compound of any one of claims 1-18.
23. A therapeutic method comprising inhibiting a p-lactamase in a 25 mammal in need of such therapy, by administering an effective inhibitory amount of a compound of any one of claims 1-18.
24. A therapeutic method comprising enhancing the activity of a P-lactam antibiotic, by administering the P-lactam antibiotic to a mammal in need thereof, in 30 combination with an effective p-lactamase inhibiting amount of a compound of any one of claims 1-18. 50 WO 00/63213 PCTIUSO0/09929
25. A therapeutic method comprising treating a P-lactam resistant bacterial infection in a mammal, by administering to the mammal an effective amount of a p-lactam antibiotic, in combination with an effective p-lactamase inhibiting amount of a compound of any one of claims 1-18. 5
26. The method of claim 25 wherein the infection is associated with Enterobacter, Citrobacter, or Serratia.
27. The method of claim 26 wherein the infection is associated with 10 Pneumococci.
28. A compound of any one of claims 1-18 for use in medical therapy.
29. The use of a compound of any one of claims 1-18 for the manufacture 15 of a medicament useful for reducing p-lactamase activity in a mammal.
30. A compound of formula I: R1 R5 20 R2 A R6 /Ny O R3 COOR 4 (I) 25 wherein: R 1 , R 2 , R 5 , and R 6 are each independently hydrogen, (C 1 -CIO)alkyl, (C 2 -CIO)alkenyl, (C 2 -C 1 )alkynyl, (C 3 -C 8 )cycloalkyl, (C-C O)alkoxy, (C 1 CIO)alkanoyl, (CI-CIO)alkanoyloxy, (CI-CIO)alkoxycarbonyl, aryl, heterocycle, halo, cyano, nitro, -COORa, -C(=0)NRbR, -OC(=0)NRbR, NRbR, or -S(O)Rd; or R, 30 and R 2 together with the carbon to which they are attached are (C 3 -C 8 )cycloalkyl or a heterocycle, wherein each (C 3 -C)cycloalkyl or heterocycle is optionally substituted with (C 1 -C 1 O)alkyl, hydroxy, halo, (C 1 - C 10 )alkoxy, (C 1 -CIO)alkanoyloxy, or (C CIO)alkoxycarbonyl; or R 5 and R 6 together with the carbon to which they are attached 51 WO 00/63213 PCT/USOO/09929 are (C 3 -C)cycloalkyl or a heterocycle, wherein each (C 3 -C)cycloalkyl or heterocycle is optionally substituted with (CI-CIO)alkyl, hydroxy, halo, (C 1 C O)alkoxy, (C- CIO)alkanoyloxy, or (CI-C O)alkoxycarbonyl; R 3 is hydrogen, (C 1 -CIO)alkyl, (C 2 -CIO)alkenyl, (C 2 -CIO)alkynyl, (C 3 5 C 8 )cycloalkyl, (C 1 -CIO)alkoxy, (C-CIO)alkanoyl, (CI-CIO)alkanoyloxy, (C CIO)alkoxycarbonyl, halo, cyano, nitro, aryl, heterocycle, -COORa, -C(=O)NRbR, -OC(=O)NRbR, NRbRe, or -S(O)Rd; R 4 is (CI-CIO)alkyl, (C 2 -CIO)alkenyl, (C 3 -C)cycloalkyl, (C 2 CIO)alkynyl, aryl, benzyl, and benzhydryl; 10 A is thio, sulfinyl, or sulfonyl; each n is independently 0, 1, or 2; each Ra is independently hydrogen, or (C 1 -C 1 O)alkyl; each Rb and R, is independently hydrogen, (CI-CIO)alkyl, (C CIO)alkoxy, phenyl, benzyl, phenethyl, or (C 1 -CIO)alkanoyl; 15 each Rd is independently (CI-C 1 O)alkyl, (CI-C 1 O)alkanoyl, aryl, heterocycle, aryl(C 1 -C 6 )alkyl, heterocycle, or heterocycle(Cl-C 6 )alkyl; wherein any (CI-CIO)alkyl, (C 2 -CO)alkenyl, (C 2 -CIO)alkynyl, (C 3 C 8 )cycloalkyl, (CI-CIO)alkoxy, (C-CIO)alkanoyl, (CI-C O)alkanoyloxy, or (C C 1 O)alkoxycarbonyl of R,, R 2 , R 3 , R 5 , and R 6 is optionally substituted with one or 20 more (e.g. 1, 2, 3, or 4) substituents independently selected from halo, hydroxy, cyano, cyanato, nitro, mercapto, oxo, aryl, heterocycle, (C 2 -C 6 )alkenyl, (C 2 C 6 )alkynyl, (C 1 -C 6 )alkoxy, (Cl-C)alkanoyl, (Cl-C)alkanoyloxy, aryl(Cl C 6 )alkanoyloxy, halo(C,-C 6 )alkanoyloxy, heterocycle(C -C)alkanoyloxy, aryloxy, (heterocycle)oxy, -COORa, (C 3 -C 8 )cycloalkyl, -C(=O)NRbRe, -OC(=O)NRbR, 25 NRbR, and -S(O)Rd; and wherein any aryl is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents independently selected from halo, hydroxy, cyano, trifluoromethyl, nitro, trifluoromethoxy, (C-C 6 )alkyl, (Cl-C)alkanoyl, (C C 6 )alkanoyloxy, (C-C)alkoxycarbonyl, -COORa, -C(=O)NRbR, -OC(=O)NRbR, 30 NRbR, and -S(O),lRd.
31. A compound of formula IV: 52 WO 00/63213 PCT/USOO/09929 Ry1 R8 A 5N o R 9 COOR 10 (IV) wherein: 10 R 7 and R 8 are each independently hydrogen, (CI-CIO)alkyl, (C 2 CIO)alkenyl, (C 2 -CIO)alkynyl, (C 3 -C 8 )cycloalkyl, (CI-CIO)alkoxy, (C- CIO)alkanoyl, (CI-CIO)alkanoyloxy, (CI-CIO)alkoxycarbonyl, aryl, heterocycle, halo, cyano, nitro, COORe, -C(=O)NRfRg, -OC(=O)NRfRg, NRfRg, or -S(O)nR; R9 is cyano, -CH=NOR,, or a radical of the following formula 15 Rk Rio is hydrogen; 20 A is thio, sulfinyl, or sulfonyl; each n is independently 0, 1, or 2; each Re is independently hydrogen, or (CI-CIO)alkyl; each Rf and Rg is independently hydrogen, (C 1 -CIO)alkyl, (C 1 CIO)alkoxy, phenyl, benzyl, phenethyl, or (C -CIO)alkanoyl; 25 each Rh is independently (C 1 -CO)alkyl, phenyl, aryl(C 1 -C 6 )alkyl, heterocycle, or heterocycle(C-C 6 )alkyl; R, is hydrogen or (C 1 -C 6 )alkyl; and R and Rk are each independently hydrogen, halo, cyano, nitro, aryl, heterocycle, (C 2 -C 6 )alkenyl, -COORe, -C(=O)NRfRg, -OC(=O)NRRg, NRRg, or 30 S(O)lRh ; wherein any (CI-CIO)alkyl, (C 2 -CIO)alkenyl, (C 2 -CjO)alkynyl, (C 3 C 8 )cycloalkyl, (CI-CIO)alkoxy, (CI-C O)alkanoyl, (CI-CIO)alkanoyloxy, or (C 1 CIO)alkoxycarbonyl of R 7 , R 8 , R, and Rk is optionally substituted with one or more 53 WO 00/63213 PCT/USOO/09929 (e.g. 1, 2, 3, or 4) substituents independently selected from halo, hydroxy, cyano, cyanato, nitro, mercapto, oxo, aryl, heterocycle, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C C)alkoxy, (C -C)alkanoyl, (C-C 6 )alkanoyloxy, aryl(C-C 6 )alkanoyloxy, halo(C 1 C 6 )alkanoyloxy, heterocycle(C,-C 6 )alkanoyloxy, aryloxy, (heterocycle)oxy, (C 3 5 C)cycloalkyl, -COORe, -C(=O)NRfRg, -OC(=O)NRfRg, NRhR, or -S(O)Rk; and wherein any aryl is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents independently selected from halo, hydroxy, cyano, trifluoromethyl, nitro, trifluoromethoxy, (C-C 6 )alkyl, (C,-C 6 )alkanoyl, (C C 6 )alkanoyloxy, (C -C)alkoxycarbonyl,-COOR., -C(=O)NRfRg, -OC(=O)NRfRg, 10 NRhR;, or -S(O)lRk; or a pharmaceutically acceptable salt thereof.
32. The compound of claim 31 wherein R 7 is aryl, heterocycle, or COORe. 15
33. The compound of claim 31 wherein R 7 is 2-pyridyl, or -COORe.
34. The compound of claim 31 wherein R, is hydrogen. 20
35. The compound of claim 31 wherein one of R and Rk is hydrogen and the other is cyano, -COORe, (C 2 -CIO)alkenyl, or heteroaryl.
36. The compound of claim 31 wherein RS is hydrogen or halo, and Rk is cyano, methoxycarbonyl, aminocarbonyl, tert-butoxycarbonyl, 2-pyridyl-N-oxide, 25 nitro, or vinyl.
37. The compound of claim 31 which is a pharmaceutically acceptable salt of a compound of formula IV wherein RI is hydrogen. 30
38. The compound of claim 31 wherein A is sulfonyl.
39. The compound of claim 31 wherein A is sulfonyl; R 7 is 2-pyridyl, carboxy or tert-butoxy carbonyl; R, is hydrogen; R is hydrogen or halo; and Rk is 54 WO 00/63213 PCT/USOO/09929 cyano, methoxycarbonyl, aminocarbonyl, tert-butoxycarbonyl, 2-pyridyl-N-oxide, nitro, or vinyl.
40. A pharmaceutical composition comprising a compound of any one of 5 claims 31-39; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
41. The composition of claim 40 further comprising a p-lactam antibiotic. 10
42. The composition of claim 41 wherein the antibiotic is amoxicillin, piperacillin, ampicillin, ceftizoxime, cefotaxime, cefuroxime, cephalexin, cefaclor, cephaloridine, or ceftazidime.
43. A method comprising inhibiting a P-lactamase by contacting said P 15 lactamase with an effective amount of a compound of any one of claims 31-39.
44. A therapeutic method comprising inhibiting a P-lactamase in a mammal in need of such therapy, by administering an effective inhibitory amount of a compound of any one of claims 31-39. 20
45. A therapeutic method comprising enhancing the activity of a p-lactam antibiotic, by administering the p-lactam antibiotic to a mammal in need thereof, in combination with an effective p-lactamase inhibiting amount of a compound of any one of claims 31-39. 25
46. A therapeutic method comprising treating a p-lactam resistant bacterial infection in a mammal, by administering to the mammal an effective amount of a plactam antibiotic, in combination with an effective p-lactamase inhibiting amount of a compound of any one of claims 31-39. 30
47. The method of claim 46 wherein the infection is associated with Enterobacter, Citrobacter, or Serratia. 55 WO 00/63213 PCTUSOO/09929
48. The method of claim 46 wherein the infection is associated with Pneumococci.
49. A compound of any one of claims 31-39 for use in medical therapy. 5
50. The use of a compound of any one of claims 31-39 for the manufacture of a medicament useful for reducing P-lactamase activity in a mammal
51. A compound of formula IV 10 R 8 A 15 COOR 1 0 (IV) wherein: R 7 and R 8 are each independently hydrogen, (CI-CIO)alkyl, (C 2 CIO)alkenyl, (C 2 -CIO)alkynyl, (C 3 -C 8 )cycloalkyl, (CI-CIO)alkoxy, (C- CIO)alkanoyl, 20 (Cl-CIO)alkanoyloxy, (CI-CIO)alkoxycarbonyl, aryl, heterocycle, halo, cyano, nitro, COORe, -C(=O)NRRg, -OC(=O)NRfRg, NRfRg, or -S(O)nRh; R 9 is cyano, -CH=NOR,, or a radical of the following formula: Rj 25 Rk Rio is (Cl-CIO)alkyl, (C 2 -CIO)alkenyl, (C 3 -C 8 )cycloalkyl, (C 2 C 1 O)alkynyl, aryl, benzyl, and benzhydryl; A is thio, sulfinyl, or sulfonyl; 30 each n is independently 0, 1, or 2; each R. is independently hydrogen, or (Cl-CIO)alkyl; each Rf and Rg is independently hydrogen, (CI-CIO)alkyl, (Cl CIO)alkoxy, phenyl, benzyl, phenethyl, or (CI-C 1 O)alkanoyl; 56 WO 00/63213 PCT/USOO/09929 each Rh is independently (C,-C 1 )alkyl, phenyl, aryl(CI-C)alkyl, heterocycle, or heterocycle(Cl-C 6 )alkyl; R, is hydrogen or (C 1 -C 6 )alkyl; and R and Rk are each independently hydrogen, halo, cyano, nitro, aryl, 5 heterocycle, (C 2 -C 6 )alkenyl, -COOR, -C(=O)NRRg, -OC(=O)NRfRg, NRfRg, or S(O).Rh; wherein any (CI-CIO)alkyl, (C 2 -CIO)alkenyl, (C 2 -C 1 O)alkynyl, (C 3 Cg)cycloalkyl, (CI-CIO)alkoxy, (Cl-CIO)alkanoyl, (CI-CIO)alkanoyloxy, or (C C 10 )alkoxycarbonyl of R 7 , Rg, R 1 and Rk is optionally substituted with one or more 10 (e.g. 1, 2, 3, or 4) substituents independently selected from halo, hydroxy, cyano, cyanato, nitro, mercapto, oxo, aryl, heterocycle, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C, C)alkoxy, (C -C)alkanoyl, (C-C 6 )alkanoyloxy, aryl(Ci-C)alkanoyloxy, halo(C 1 C)alkanoyloxy, heterocycle(C-C 6 )alkanoyloxy, aryloxy, (heterocycle)oxy, (C 3 C 8 )cycloalkyl, -COOR, -C(=0)NRfRg, -OC(=O)NRfRg, NRhR., or -S(O)nRk; and 15 wherein any aryl is optionally substituted with one or more (e.g. 1, 2, 3, or 4) substituents independently selected from halo, hydroxy, cyano, trifluoromethyl, nitro, trifluoromethoxy, (C -C 6 )alkyl, (C -C 6 )alkanoyl, (C C 6 )alkanoyloxy, (Cl-C 6 )alkoxycarbonyl, -COORe, -C(=O)NRfRg, -OC(=O)NRfRg, NRhR1, or -S(O)Rk. 57
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12948299P | 1999-04-15 | 1999-04-15 | |
US60/129482 | 1999-04-15 | ||
PCT/US2000/009929 WO2000063213A1 (en) | 1999-04-15 | 2000-04-14 | Beta-lactamase inhibiting compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
AU4238600A true AU4238600A (en) | 2000-11-02 |
AU773013B2 AU773013B2 (en) | 2004-05-13 |
Family
ID=22440183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU42386/00A Ceased AU773013B2 (en) | 1999-04-15 | 2000-04-14 | Beta-lactamase inhibiting compounds |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1169323A1 (en) |
JP (1) | JP2002542249A (en) |
AT (1) | ATE330960T1 (en) |
AU (1) | AU773013B2 (en) |
CA (1) | CA2371389A1 (en) |
DE (1) | DE60029023T2 (en) |
MX (1) | MXPA01010409A (en) |
WO (1) | WO2000063213A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0966471B1 (en) | 1997-12-29 | 2002-06-12 | Research Corporation Technologies, Inc | 2-beta-substituted-6-alkylidene penicillanic acid derivatives as beta-lactamase inhibitors |
US6407091B1 (en) | 1999-04-15 | 2002-06-18 | Research Corporation Technologies, Inc. | β-lactamase inhibiting compounds |
JP2002356427A (en) * | 2001-05-30 | 2002-12-13 | Shionogi & Co Ltd | beta-LACTAMASE INHIBITOR |
JP2005502687A (en) | 2001-07-24 | 2005-01-27 | アラムクス エルエルシー | 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors |
JP2005525399A (en) | 2002-04-04 | 2005-08-25 | アラムクス エルエルシー | Inhibitors of serine and metallo-β-lactamases |
CN102731530B (en) * | 2011-04-07 | 2016-05-04 | 天津市医药集团技术发展有限公司 | Cephalosporin compound and synthetic method thereof and application |
CN107021893A (en) * | 2017-05-05 | 2017-08-08 | 贵州师范学院 | Thio acyl Ammonium Salt Ionic Liquid of one class and preparation method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5629306A (en) * | 1994-12-09 | 1997-05-13 | Research Corporation Technologies, Inc. | 7-alkylidene cephalosporanic acid derivatives and methods of using the same |
US5760027A (en) * | 1996-12-06 | 1998-06-02 | Research Corporation Technologies, Inc. | Use of 7-alkylidene cephalosporins to inhibit elastase activity |
-
2000
- 2000-04-14 EP EP00922157A patent/EP1169323A1/en not_active Withdrawn
- 2000-04-14 WO PCT/US2000/009929 patent/WO2000063213A1/en not_active Application Discontinuation
- 2000-04-14 AU AU42386/00A patent/AU773013B2/en not_active Ceased
- 2000-04-14 CA CA002371389A patent/CA2371389A1/en not_active Abandoned
- 2000-04-14 DE DE60029023T patent/DE60029023T2/en not_active Expired - Fee Related
- 2000-04-14 JP JP2000612303A patent/JP2002542249A/en active Pending
- 2000-04-14 MX MXPA01010409A patent/MXPA01010409A/en not_active Application Discontinuation
- 2000-04-14 AT AT03015238T patent/ATE330960T1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE60029023D1 (en) | 2006-08-03 |
JP2002542249A (en) | 2002-12-10 |
ATE330960T1 (en) | 2006-07-15 |
AU773013B2 (en) | 2004-05-13 |
CA2371389A1 (en) | 2000-10-26 |
MXPA01010409A (en) | 2003-12-11 |
EP1169323A1 (en) | 2002-01-09 |
WO2000063213A1 (en) | 2000-10-26 |
DE60029023T2 (en) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7488724B2 (en) | 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors | |
US20060178357A1 (en) | Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases | |
JP2618119B2 (en) | Thioalkylthiocephalosporin derivatives | |
EP0966471B1 (en) | 2-beta-substituted-6-alkylidene penicillanic acid derivatives as beta-lactamase inhibitors | |
AU773013B2 (en) | Beta-lactamase inhibiting compounds | |
US5134138A (en) | Phenacylpyridiniothiocephalosporins | |
US6407091B1 (en) | β-lactamase inhibiting compounds | |
US5362724A (en) | Thioalkylthio carbacephalosporin derivatives | |
US7022691B2 (en) | Inhibitors of serine and metallo-β-lactamases | |
EP1359153B1 (en) | Beta-lactamase inhibiting compounds | |
JP3218363B2 (en) | Cephem compound, method for producing the same, and antibacterial agent containing the compound | |
EP0338824A2 (en) | Esters of 6-beta-(alpha-oxyimino)-acylamino-penicillanic acid derivatives | |
CZ163291A3 (en) | novel beta-lactam compounds | |
JPH01203393A (en) | Novel cephalosporin compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |